8. In patients with COPD with a previous or recent history of exacerbations, we recommend education and case management that includes direct access to a health-care specialist at least monthly to prevent severe acute exacerbations of COPD, as assessed by decreases in hospitalizations (Grade 1C).
Underlying Values and Preferences:
Th is recommendation places high value on reducing hospitalizations for COPD exacerbations, as these are associated with increased morbidity and mortality.
9. In patients with moderate to severe COPD, we suggest education together with an action plan but without case management does not prevent severe acute exacerbations of COPD, as assessed by a decrease in ED visits or hospitalizations over a 12-month period (Grade 2C).
10.
For patients with COPD, we suggest education with a written action plan and case management for the prevention of severe acute exacerbations of COPD, as assessed by a decrease in hospitalizations and ED visits (Grade 2B).
Underlying Values and Preferences:
Th is recommendation places high value on reducing COPD-related hospitalizations, as these are associated with increased morbidity and mortality. Hospitalizations were believed to best refl ect exacerbations because increased physician visits or increased medication use could be a result of the intervention to prevent an exacerbation. High value was also placed on changes in individuals with a history of exacerbations and on outcomes that specifi cally identifi ed COPD-related hospitalizations. Th e recommendation refl ects the fact that one study reported increased mortality in the intervention group. Although we do not know the reason for increased mortality in this one study, patients with underlying severe disease and clinical instability need close attention and careful follow-up. Th is point emphasizes that a specially trained Underlying Values and Preferences: Th is recommendation places value on the combination of short-acting muscarinic antagonist plus long-acting b 2 -agonist therapy reducing the risk of acute exacerbations of COPD compared with the use of long-acting b 2 -agonist therapy alone and the comparative value of short-acting muscarinic antagonist plus long-acting b 2 -agonist therapy improving lung function, quality of life, and dyspnea scores compared with long-acting b 2 -agonist monotherapy. No data favor one therapy over the other in terms of COPD hospitalizations. This recommendation also acknowledges that there are no signifi cant diff erences in serious adverse events with the combined use of shortacting muscarinic antagonist plus long-acting b 2 -agonist therapy vs long-acting b 2 -agonist therapy alone.
20.
For patients with stable moderate, severe, and very severe COPD, we recommend maintenance combination inhaled corticosteroid/long-acting b 2 -agonist therapy (and not inhaled corticosteroid monotherapy) compared with placebo to prevent acute exacerbations of COPD (Grade 1B).
Underlying Values and Preferences:
Th is recommendation places high value on reducing the risk of acute exacerbations of COPD together with slowing the rate of decline in health-related quality of life and a relatively lower value on the risks and consequences of oral candidiasis, hoarseness and dysphonia, bruising, and pneumonia.
21.
For patients with stable moderate, severe, and very severe COPD, we recommend maintenance combination inhaled corticosteroid/long-acting b 2 -agonist therapy compared with long-acting b 2 -agonist monotherapy to prevent acute exacerbations of COPD (Grade 1C).
Underlying Values and Preferences:
Th is recommendation places high value on reducing the risk of acute exacerbations of COPD together with improved healthrelated quality of life, reduced dyspnea, less rescue medication use, and improved lung function and a relatively lower value on the risks and consequences of oral candidiasis, upper respiratory tract infections, and pneumonia.
22. For patients with stable moderate to very severe COPD, we recommend maintenance combination inhaled corticosteroid/long-acting b 2 -agonist therapy compared with inhaled corticosteroid monotherapy to prevent acute exacerbations of COPD (Grade 1B).
Th is recommendation places high value on reducing the risk of acute exacerbations of COPD together with the comparative mortality benefi t of combination inhaled corticosteroid/ long-acting b 2 -agonist therapy, acknowledging that there were no signifi cant diff erences in serious adverse events or incidence of pneumonia between the groups. Th is recommendation does not support the use of inhaled corticosteroid monotherapy in COPD.
23. For patients with stable COPD, we recommend inhaled long-acting anticholinergic/long-acting b 2 -agonist therapy or inhaled long-acting anticholinergic monotherapy, since both are eff ective to prevent acute exacerbations of COPD (Grade 1C).
Th is recommendation places high value on reducing the risk of acute exacerbations of COPD.
For patients with stable COPD, we recommend maintenance combination of inhaled corticosteroid/ long-acting b 2 -agonist therapy or inhaled long-acting anticholinergic monotherapy, since both are eff ective to prevent acute exacerbations of COPD (Grade 1C).

Underlying Values and Preferences:
Th is recommendation places high value on reducing the risk of acute exacerbations of COPD and a relatively lower value on the risks and consequences of pneumonia.
25.
For patients with stable COPD, we suggest maintenance combination of inhaled long-acting anticholinergic/corticosteroid/long-acting b 2 -agonist therapy or inhaled long-acting anticholinergic monotherapy, since both are eff ective to prevent acute exacerbations of COPD (Grade 2C).
Underlying Values and Preferences:
PICO 3: In Patients Aged . 40 Years Who Are Previous or Current Smokers With COPD, Does Oral Therapy Prevent/Decrease Acute Exacerbations of COPD?
26. For patients with moderate to severe COPD, who have a history of one or more moderate or severe COPD exacerbations in the previous year despite optimal maintenance inhaler therapy, we suggest the use of a long-term macrolide to prevent acute exacerbations of COPD (Grade 2A).
Underlying Values and Preferences:
Th is recommendation places high value on the prevention of COPD exacerbations. However, clinicians prescribing macrolides need to consider in their individual patients the potential for prolongation of the QT interval and hearing loss as well as bacterial resistance. Th e duration and exact dosage of macrolide therapy are unknown.
27.
For patients with an acute exacerbation of COPD in the outpatient or inpatient setting, we suggest that systemic corticosteroids be given orally or intravenously to prevent hospitalization for subsequent acute exacerbations of COPD in the fi rst 30 days following the initial exacerbation (Grade 2B).
Underlying Values and Preferences:
We place high value on reducing recurrent exacerbations in the fi rst 30 days following an initial acute exacerbation of COPD by treating the exacerbation with systemic corticosteroids. This recommendation takes into consideration the risks associated with the short-term use of systemic corticosteroids, which include hyperglycemia, weight gain, and insomnia, but the benefi ts of this intervention are believed to outweigh the risks. The use of systemic corticosteroids to treat an acute exacer bation has not been shown to reduce acute exacerbations beyond the 30-day window. Furthermore, no evidence supports the use of long-term corticosteroids to reduce acute exacerbations of COPD, and the risks of hyper glycemia, weight gain, infection, osteoporosis, and adrenal suppression far outweigh any benefi ts.
28.
For patients with an acute exacerbation of COPD in the outpatient or inpatient setting, we recommend that systemic corticosteroids not be given orally or intravenously for the sole purpose of preventing hospitalization due to subsequent acute exacerbations of COPD beyond the fi rst 30 days following the initial acute exacerbation of COPD (Grade 1A).
Remark : Th is does not preclude the use of systemic corticosteroids for the treatment of acute exacerbations of COPD.
Underlying Values and Preferences:
We place high value on reducing recurrent exacerbations in the fi rst 30 days following an initial acute exacerbation of COPD by treating the exacerbation with systemic corticosteroids. Th is recommendation takes into consideration the risks associated with short-term use of systemic corticosteroids, which include hyperglycemia, weight gain, and insomnia, but the benefits of this intervention are believed to outweigh the risks. Th e use of systemic corticosteroids to treat an acute exacerbation has not been shown to reduce acute exacerbations beyond the 30-day window. Furthermore, no evidence supports the use of long-term corticosteroids to reduce acute exacerbations of COPD, and the risks of hyperglycemia, weight gain, infection, osteoporosis, and adrenal suppression far outweigh any benefi ts.
29.
For patients with moderate to severe COPD with chronic bronchitis and a history of at least one exacerbation in the previous year, we suggest the use of rofl umilast to prevent acute exacerbations of COPD (Grade 2A).
Underlying Values and Preferences:
Clinicians prescribing rofl umilast need to advise their patients of the potential side eff ects of weight loss and diarrhea. Patients may have to discontinue the therapy because of side eff ects. Th e decision to prescribe this medication should also be informed by the fact that there are limited data for supplemental eff ectiveness in patients concurrently using inhaled therapies.
For stable patients with COPD, we suggest treatment with oral slow-release theophylline twice daily to prevent acute exacerbations of COPD (Grade 2B).
Underlying Values and Preferences:
Physicians should inform their patients with COPD who are being treated with maintenance bronchodilator therapy and inhaled corticosteroids and who continue to have periodic exacerbations that theophylline may reduce the number of exacerbations. Patient decisions may also be informed by the relatively narrow therapeutic window with respect to adverse effects of treatment with theophylline. Physicians should use the lowest eff ective dose in prescribing theophylline in order to avoid adverse eff ects. Th eophylline use requires vigilance on the part of the physician in order to avoid serious drug interactions, which lead to changes in serum theophylline levels. Patients should be advised that changes in tobacco use habits will aff ect serum theophylline levels and that they should inform their physicians if they stop smoking while taking theophylline.
31.
For patients with moderate to severe COPD and a history of two or more exacerbations in the previous 2 years, we suggest treatment with oral N-acetylcysteine to prevent acute exacerbations of COPD (Grade 2B).
Underlying Values and Preferences:
Physicians should inform their patients with COPD who are being treated with maintenance bronchodilator therapy and inhaled corticosteroids and who continue to have periodic exacerbations that N-acetylcysteine may reduce the number of exacerbations. Patient decisions may also be informed by the low risk of adverse eff ects from treatment with N-acetylcysteine.
32. For stable outpatients with COPD who continue to experience acute exacerbations of COPD despite maximal therapy designed to reduce acute exacer bations of COPD, we suggest that oral carbocysteine could be used to prevent acute exacerbations where this therapy is available (Ungraded Consensus-Based Statement).
Th is suggestion places high value on preventing acute exacerbations of COPD, with minimal risks associated with carbocysteine. Th e main adverse events reported in studies were mild GI symptoms.
33.
For patients with moderate to severe COPD who are at risk for COPD exacerbations, we do not recommend using statins to prevent acute exacerbations of COPD (Grade 1B).
Introduction
COPD is a common disease with substantial associated morbidity and mortality. Patients with COPD usually have a progression of airfl ow obstruction that is not fully reversible and can lead to a history of progressively worsening breathlessness, that can impact daily activities and health-related quality of life. 1 -3 COPD is the fourth leading cause of death in Canada 4 and the third leading cause of death in the United States where it claimed 133,965 lives in 2009. 5 In 2011, 12.7 million US adults were estimated to have COPD. 6 However, approximately 24 million US adults have evidence of impaired lung function, indicating an underdiagnosis of COPD. 7 Although 4% of Canadians aged 35 to 79 years selfreported having been given a diagnosis of COPD, direct measurements of lung function from the Canadian Health Measures Survey indicate that 13% of Canadians have a lung function score indicative of COPD. 4 COPD is also costly. In 2009, COPD caused 8 million offi ce visits, 1.5 million ED visits, 715,000 hospitalizations, and 133,965 deaths in the United States. 8 In 2010, US costs for COPD were projected to be approximately $49.9 billion, including $29.5 billion in direct health-care expenditures, $8.0 billion in indirect morbidity costs, and $12.4 billion in indirect mortality costs. 9 Exacerbations account for most of the morbidity, mortality, and costs associated with COPD. Th e economic burden associated with moderate and severe exacerbations in Canada has been estimated to be in the range of $646 million to $736 million per annum. 10 Th is value may be an underestimate given that the prevalence of moderate exacerbations is not well documented, COPD is underdiagnosed, and the rate of hospitalization due to COPD is increasing. 11 Exacerbations are to COPD what myocardial infarctions are to coronary artery disease: Th ey are acute, trajectorychanging, and oft en deadly manifestations of a chronic disease. Exacerbations cause frequent hospital admissions, relapses, and readmissions 12 ; contribute to death during hospitalization or shortly thereaft er 12 ; reduce quality of life dramatically 12 , 13 ; consume financial resources 12 , 14 ; and hasten a progressive decline in pulmonary function, a cardinal feature of COPD. Hospitalization due to exacerbations accounts for . 50% of the cost of managing COPD in North America and Europe. 15 , 16 COPD exacerbation has been defi ned as an event in the natural course of the disease characterized by a baseline change in the patient's dyspnea, cough, and/or sputum that is beyond the normal day-to-day variations, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD . 17 , 18 Exacerbation in clinical trials has been defined for operational reasons on the basis of whether an increase in treatment beyond regular or urgent care is required in an ED or a hospital. Exacerbation treatment in clinical trials usually is defi ned by the use of antibiotics, systemic corticosteroids, or both. 19 Th e severity of the exacerbation is then ranked or stratifi ed according to the outcome: mild, when the clinical symptoms are present but no change in treatment or outcome is recorded; moderate, when the event results in a change in medication such as the use of antibiotics and systemic corticosteroids; or severe, when the event leads to a hospitalization. 1 Two-thirds of exacerbations are associated with respiratory tract infections or air pollution, but one-third present without an identifi able cause. 17 Exacerbations remain poorly understood in terms of not only cause but also treatment and prevention. Although the management of an acute exacerbation has been the primary focus of clinical trials, the prevention of acute exacerbations has not been a major focus until recently. Most current COPD guidelines focus on the general diagnosis and evaluation of the patient with COPD, the management of stable disease, and the diagnosis and management of acute exacerbations. 1 , 20 Although current COPD guidelines state that prevention of exacerbations is possible, little guidance is provided to the clinician regarding current available therapies for the prevention of COPD exacerbations. 1 , 20 Moreover, recent new therapies have promise in preventing acute exacerbations of COPD (AECOPDs) and would benefit from critical review of their efficacy in the exacerbation prevention management. 21 -23 The American College of Chest Physicians (CHEST) and Canadian Th oracic Society (CTS) jointly commissioned this evidence-based guideline on the prevention of COPD exacerbations to fi ll this important void in COPD management.
Th e overall objective of this CHEST and CTS joint evidence-based guideline (AECOPD Guideline) was to create a practical, clinically useful document describing the current state of knowledge regarding the prevention of acute exacerbations of COPD according to major categories of prevention therapies. We accomplished this by using recognized document evaluation tools to assess and choose the most appropriate studies and evidence to extract meaningful data and to grade the level of evidence supporting the recommendations in a balanced and unbiased fashion. Th e AECOPD Guideline is unique not only for its topic, but also for the firstin-kind partnership between two of the largest thoracic societies of North America. Th e CHEST Guidelines Oversight Committee (GOC) in partnership with the CTS COPD Clinical Assembly launched this project with the objective that a systematic review and critical evaluation of the published literature by clinical experts and researchers in the fi eld of COPD would lead to a series of recommendations to assist clinicians in their management of the patient with COPD. Th is guideline is unique because a group of interdisciplinary clinicians who have special expertise in COPD clinical research and care led the development of the guideline process with the assistance of methodologists.
Materials and Methods
Expert Panel Composition
Members from CHEST and CTS were selected to participate on the AECOPD Guideline panel based on their expertise in the field. CTS representatives were members of the CTS COPD Clinical Assembly. Members who were interested in serving on the guideline panel were asked to submit their curriculum vitae, statement of interest, and confl ict of interest disclosure form to the CHEST GOC for review. The final panel comprised a chair from CHEST and vice-chair from CTS as well as eight panelists from CHEST and nine from CTS who are experts in pulmonology and respiratory therapy. Panelists were assigned to one of three writing groups that addressed each key question. Th e groups were referred to as PICO groups because the key questions were developed using the PICO format, which defi nes the population, intervention, comparator, and outcome of interest. 
Confl icts of Interest
The CHEST GOC reviewed all panel nominees, including the three methodologists, for their confl icts of interest. Aft er review, nominees who reported no substantial confl icts of interest were approved, and nominees with potential confl icts of interest deemed to be manageable were "approved with management. " Panelists approved with management were prohibited from writing and voting on treatment-related recommendations. Th ey were allowed to contribute to writing the background sections of the guidelines and to participate in discussions of controversial recommendations. Th e chair was charged with reviewing any writing submitted by panelists who were approved with management. A grid tracking the confl icts of interest for each recommendation was created for each PICO writing group at the time of voting on the controversial recommendations. Th e three confl ict of interest grids can be found in e- Tables 1 to 3 .
Formulation of Key Questions
Th e AECOPD Guideline Executive Committee developed three key questions using the PICO format, which were then reviewed and revised by each PICO writing group. The three PICO questions that addressed the prevention of acute exacerbations of COPD were nonpharmacologic therapies, inhaled therapies, and oral therapies ( Table 1 ) . Th e outcome of interest was preventing acute exacerbations, including those requiring change in medication (antibiotic, prednisone, or both), ED visits and hospital admissions and readmissions, unscheduled physician visits, change in location of care, time to fi rst exacerbation, or exacerbation rate. Systematic reviews were conducted for interventions identifi ed in each PICO question, starting with a search for guidelines and systematic reviews. A further explanation of these processes was published separately. 24 
Defi nitions of Exacerbations
Exacerbation and COPD severity is noted when data were available to characterize the level of impairment or exacerbation severity. Exacerbations were defi ned as events that required a medication intervention with antibiotics, systemic corticosteroids, or both, and the severity of exacerbations was characterized by the location of care (home, ED, or hospital). Mild exacerbations were defined by adjustments in bronchodilator or inhaled corticosteroid therapy; moderate exacerbations were lower respiratory tract events treated with antibiotics, corticosteroids, or both agents; and severe exacerbations required ED visits or hospitalization. For the purpose of these guidelines, COPD was defined as a postbronchodilator FEV 1 /FVC , 0.7. Mild COPD was further stratifi ed by an FEV 1 Ն 80% predicted, moderate COPD by an FEV 1 50% to , 79% predicted, severe COPD by an FEV 1 30% to 49% predicted, and very severe COPD by an FEV 1 , 30% predicted.
Literature Searches
All panelists reviewed the PICO questions and fi nalized the search terms, inclusion and exclusion criteria, and databases that would be searched ( Table 2 ). The Guidelines International Network (GIN) Library and National Guideline Clearinghouse were used to search for guidelines on COPD, and PubMed and the Cochrane Library were used to search for systematic reviews and primary literature.
Th e searches for guidelines were conducted on January 30, 2013, and included all guidelines published up to that date. Th e GIN search netted 26 guidelines, whereas the National Guidelines Clearinghouse search netted 24; only six of these were not found in the GIN search. In total, eight guidelines were considered relevant and were assessed for quality using the AGREE (Appraisal of Guidelines Research & Evaluation) II instrument. 25 Guidelines were excluded if they did not cover one of the three interventions (nonpharmacologic therapies, inhaled therapies, and oral therapies), did not cover the outcome of interest (prevention of acute exacerbations of COPD), or were not an evidence-based guideline.
Th e Cochrane search for systematic reviews took place on April 25, 2013, and was limited to systematic reviews published between 2007 and 2013. Th e PubMed search was conducted on April 29, 2013 , and was limited to reviews published between 2008 and 2013. Th e search of the Cochrane Library resulted in 127 systematic reviews, and an additional 14 systematic reviews were found in the PubMed search. Th e systematic reviews were categorized by topic and sent to the three PICO groups for study selection. Relevant systematic reviews were assessed for quality using the DART (Documentation and Appraisal Review Tool) 26 to further determine whether they would be used to directly inform the evidence base for recommendations. Any fair-or good-quality • National Guidelines Table 1 legend for expansion of other abbreviation.
TABLE 2
] (continued) systematic reviews used in this manner were updated through the search strategies used by the review authors. Systematic reviews were also scanned for references that could further inform the primary literature searches.
Literature Searches by PICO Group
Th e PICO 1 nonpharmacologic therapies group reviewed 49 systematic reviews and determined that 15 were relevant. Of the 15 systematic reviews, four were used to directly inform the evidence base. Th e PICO 1 group conducted primary literature searches and reviews for the questions on education, action plans, case management, and smoking cessation because existing systematic reviews did not meet the predefi ned defi nitions for these interventions. Th e PICO 2 inhaled therapies group reviewed 49 systematic reviews and determined that 30 were relevant. Of the 30 systematic reviews, 11 were used to directly inform the evidence base. The PICO 3 oral therapies group reviewed 27 systematic reviews and determined that eight were potentially relevant. Th e PICO 3 group also conducted primary literature reviews because the extracted systematic reviews did not suffi ciently address all the drug classes. Additional details on literature searches and study selection can be found in e-Appendix 1 .
Study Selection and Data Extraction
A methodologist assigned to each PICO group conducted the initial literature searches and the fi rst-round title and abstract review to exclude studies not related to COPD based on the inclusion and exclusion criteria shown in Table 2 . Th e panelists reviewed the studies identifi ed for exclusion and divided into pairs to apply the inclusion and exclusion criteria to the studies initially screened for inclusion. All recommendations were made independently in parallel and then compared. Disagreements were resolved through discussion and further consultation with the methodologist if needed. Panelists were divided into pairs for data extraction, with one performing data extraction and the other independently reviewing the initial data extraction. Th e methodologists assisted in building evidence tables and added data necessary for conducting any meta-analyses. Data from new studies identifi ed in updated searches of published systematic reviews and data from de novo reviews were extracted into evidence tables (e-Tables 4, 5 ).
Quality Assessment
Th e methodologists assessed the quality of the guidelines using AGREE II 25 and DART. 26 Randomized controlled trials (RCTs) were assessed using the Cochrane Risk of Bias tool. 27 R. D. developed a quality assessment tool for intervention studies, including RCTs and observational studies, that was used to assess the quality of any observational studies included in the evidence reviews. 28 , 29 As the methodologists were assessing the quality of the studies, they also considered how exacerbations were counted 30 and whether the outcomes were treated as primary or secondary outcomes.
Meta-analyses and Evidence Profi les
Upon completion of the evidence tables and quality assessment, Review Manager version 5.1 soft ware (Th e Cochrane Collaboration) was used to create meta-analyses on topics where data were homogeneous and poolable based on the measured outcomes. Studies with a shorter follow-up period (ie, 3-4 months) were examined separately from those with a longer follow-up period (ie, Ն 6 months). When possible, meta-analyses included studies from published systematic reviews as well as new studies identifi ed through updated searches. Meta-analyses were also used for data compiled from de novo reviews. Heterogeneity of the pooled results was assessed using a x 2 test and Higgins I 2 , and a forest plot was examined for consistency of the results. A Higgins I 2 Ն 50% and P , .05 indicated statistically significant heterogeneity.
The random-effects model was chosen a priori as the appropriate model for pooling data. Results from the meta-analyses can be found in e- Tables 6 and 7 .
Grading the Evidence Profi les
Evidence profi les were produced using GRADEpro soft ware (GRADE Working Group). Th e GRADEpro soft ware ranked the quality of the body of evidence using four categories: high, moderate, low, and very low ( Table 3 ) . 31 Th e quality of the evidence was then used to determine the strength of the supporting evidence that informed a recommendation (see the next section, Recommendations, for more information on grading recommendations). Additional information on grading the body of evidence can be found in "Methodologies for the Development of CHEST Guidelines and Expert Panel Reports." 24 Evidence profiles can be found in e- Tables 8 to 10 .
Recommendations
Evidence tables, meta-analyses, evidence profiles, and all the studies included in the evidence review informed the recommendations and their associated grades. Recommendations were graded using the CHEST grading system ( Table 4 ) . 24 , 32 Values and preferences statements are considered part of a recommendation, and they appear with the recommendation in the main text of the guideline as well as in the summary of recommendations and executive summary. Panelists who were approved with management refrained from writing treatment-related recommendations and were assigned to draft ing supporting text. Only one panelist in the PICO 1 nonpharmacologic therapies group was prohibited from writing treatment-related recommendations. Two panelists in the PICO 2 inhaled therapies group were permitted to write recommendations, and they worked with the other panelists in the group to draft supporting text. Th ree panelists in the PICO 3 oral therapies group were permitted to write recommendations, and they worked with the other panelists to draft the supporting text. Recommendations were not made in instances where the panelists believed the data insuffi cient or inconclusive to warrant a recommendation. In instances where there was insuffi cient evidence but a recommendation was still warranted, a weak suggestion was developed, and consensus based (CB) replaced the grade. Completed recommendations/suggestions and supporting text were reviewed by each PICO group and revised before shared with the entire panel.
Recommendations/suggestions and supporting text were sent to the panelists along with a survey of the recommendations/suggestions asking panelists to identify any recommendations deemed controversial based on wording, grade, or both. Any recommendations identifi ed as controversial in the survey as well as any CB suggestions were presented and discussed during a live webinar. Panelists were then sent an additional survey with the revised statements resulting from the discussions and asked to vote on the recommendations/suggestions. Th e confl ict of interest grids were sent with the voting survey, and panelists approved with management were on the honor system to refrain from voting on any treatment-related recommendations. Based on CHEST policy, 75% participation and 80% consensus were required for recommendations/suggestions to pass. Any recommendations/suggestions that did not pass were revised based on feedback included in the voting survey, and a new survey was sent with the incorporated changes.
Review Process
After the AECOPD Guideline Executive Committee provided final approval, the manuscript was sent to the Executive of the Canadian Respiratory Guidelines Committee (CRGC), CTS Executive, and CHEST reviewers representing the GOC, Board of Regents, and NetWorks. Th e CHEST NetWorks of interested members in the areas of airways disorders and clinical pulmonary medicine reviewed the manuscript content. All reviewed both content and methods for consistency, accuracy, and completeness. Th e CHEST Journal peer-review process was integrated with these reviews. All ideas for modifi cation were marked as mandatory or suggested by the GOC, responded to or justifi ed by the authors, and tracked through multiple rounds of review.
Dissemination, Implementation, and Knowledge Translation
Aft er publication, the guidelines were promoted by both CHEST and CTS to a wide audience of physicians, other health-care providers, and the public through multiple avenues. Joint press releases were made to both the lay and the medical media, with major outreach eff orts to all relevant print, broadcast, and Internet media. Panelists located in various large media markets were identifi ed as potential spokespersons for interviews. In addition to the guidelines, a companion article was prepared to help with implementation.
American College of Chest Physicians: Social media promotion was facilitated over Twitter, Facebook, CHEST e-Communities, internal and external blogs, and other communication routes. Blast communications were sent to CHEST members with links to the publication and postings on the CHEST website.
In addition to publication in CHEST , other derivative products were prepared to help with implementation, including slide sets, algorithms, and other clinical tools. Th ese derivative products were posted on the CHEST website and made available in CHEST Guidelines expected to launch at a later date. CHEST Guidelines will be the repository for the most current recommendations/suggestions from all CHEST guidelines, consensus statements, and hybrid documents. Th is online repository will also house a collection of related resources.
Canadian Thoracic Society:
The knowledge translation plan was developed by (1) identifying key messages from the guideline recommendations, (2) determining the target audiences for each message, (3) seeking out the most credible messenger and engaging his or her interest in becoming involved in the communication, and (4) launching a knowledge translation strategy grounded in the best available research evidence. Th e CTS has a framework for guideline dissemination and implementation, with concurrent evaluation led by the CRGC based on the Knowledge-to-Action Framework. 33 Traditional knowledge diffusion avenues, such as presentations at scientific meetings and publication in peer-reviewed journals, will be used. Th e guideline was promoted through the CRGC website ( www.respiratoryguidelines.ca ). Targeted promotional communications were sent to provincial lung associations across Canada and distributed through CTS e-bulletins to individuals and organizations with an interest in this topic area.
CTS used other modes of communication such briefi ng notes, websites, creative media, and emerging online technologies (eg, podcasting, accredited webinars). To disseminate more broadly to the general public, traditional media and social media were engaged. Point-of-care tools for implementation of guideline recommendations were developed, including a trifold pocket brochure (Slim Jim) and electronic versions of the guideline for the smart phone and tablet. A slide kit for teaching and self-directed learning were posted for viewing and downloading on the CRGC website.
Endorsement
Associations were invited to consider endorsing the approved guideline for listing in the fi nal publication. Th ese organizations were requested to help to promote the publication to their memberships through newsletters, websites, and other means.
Updating
CHEST guidelines and consensus statements are living documents subject to updating as necessary. Annual reviews begin 1 year aft er publication. Th e CHEST GOC and CTS CRGC have established criteria to select and prioritize projects for updating, including the publication of new studies where the results might affect either the direction or the strength of the existing recommendations. Other criteria focus on new interventions or changes in practice that might require updating existing recommendations. Th e long-term goal is to maintain the currency of the guidance documents.
Recommendations for the Prevention of Acute Exacerbations of COPD PICO 1: Do Nonpharmacologic Treatments and Vaccinations Prevent/Decrease Acute Exacerbations of COPD?
Eff ective support and management of individuals at risk for an AECOPD demands a comprehensive and patient-centered approach. Th e widely adopted Chronic Care Model 34 , 35 recognizes that improvements in care require approaches incorporating patient-, provider-, and system-level interventions. Key elements of the Chronic Care Model are the health system, delivery system design (including case management), decision support, clinical information systems, self-management support (including assessment, goal setting, action planning, problem solving, and follow-up), and community. Th e importance of incorporating nonpharmacologic approaches into the care of this population is refl ected in international guidelines for COPD management. 20 , 36 , 37 PICO question 1 addresses the following categories:
(1) pneumococcal vaccinations; (2) infl uenza vaccinations; (3) smoking cessation programs; (4) pulmonary rehabilitation; (5) education, action plans, and case management; and (6) telemonitoring ( Table 1 ) . A defi nition of each intervention is specifi ed in the text
that accompanies each recommendation. Th e present taxonomy and defi nitions of interventions diff er from that of several other publications 38 -40 related to nonpharmacologic management. We chose to create exclusive, clearly defi ned, and comparable categories and to characterize evolving technologies, such as telemonitoring.
Th ese topics may be considered complex interventions 41 in that they contain multiple interacting components and possess nonlinear causal pathways subject to a host of variables. 42 Rigorous evaluation of complex interventions can be complicated by numerous factors, including the need to adapt interventions to local contexts and issues of feasibility and acceptability. 43 Many of the nonpharmacologic trials have limitations with respect to such methodological aspects as how the intervention was standardized and the details of the experimental treatment and comparator as they were implemented. Prevention of exacerbations oft en was not the primary outcome for many studies examining the effi cacy and eff ectiveness of nonpharmacologic interventions, thus limiting our ability to make defi nitive recommendations.
We recognize that some interventions may have benefi cial outcomes relevant to overall health and quality of life but are insuffi cient to recommend their use to prevent exacerbations.
Pneumococcal Vaccine: Th e presence of underlying medical conditions such as COPD increases the risk for pneumococcal disease and its complications. Hospitalization rates for pneumococcal pneumonia are higher in patients with COPD than in the general population. 44 , 45 Pneumococcal vaccinations are eff ective for reducing the risk of infectious disease and may be benefi cial in reducing infectious-related exacerbations in COPD. 46 Patients with COPD with persistent lowerairway bacterial colonization, those with Streptococcus pneumoniae in sputum, and those with newly acquired Streptococcus pneumonia have a signifi cantly increased risk of COPD exacerbation. 47 were noted in the time to fi rst exacerbation of COPD or in the number of exacerbations, cases of pneumonia, or hospitalizations, but the study was not powered to address these issues.
We also found one study that examined the additive eff ect of pneumococcal vaccine and infl uenza vaccine on acute exacerbations in patients with chronic lung diseases. 54 In this open-label RCT in 167 subjects randomly assigned to both vaccines compared with infl uenza vaccine alone, fewer episodes of infectious-related acute exacerbations were experienced over a 2-year period ( P 5 .022).
1. In patients with COPD, we suggest administering the 23-valent pneumococcal vaccine as part of overall medical management but did not find sufficient evidence that pneumococcal vaccination prevents acute exacerbations of COPD (Grade 2C).
Underlying Values and Preferences:
Th is recommendation places high value on the benefi ts of pneumococcal vaccination for general health, and we endorse existing guidelines that recommend it for patients with COPD. Although evidence does not specifi cally support using the vaccine for the prevention of acute exacerbations, multiple bodies, including the CDC and World Health Organization (WHO), recommend the use of pneumococcal vaccine for all adults aged Ն 65 years and in those aged 19 to 64 years with underlying medical conditions such as COPD that put them at greater risk of serious pneumococcal infection.
Infl uenza Vaccine:
Annual infl uenza vaccination is the primary means of infl uenza prevention and has been recommended since 2010 for all persons aged Ն 6 months who do not have contraindications. 55 Infl uenza infection is associated with excessive mortality and morbidity in COPD that include detrimental eff ects on disease progression and increased risk of hospitalization. 1 , 20 , 36 , 37 , 56 , 57 Th e evidence supporting the recommendation for infl uenza vaccine use in COPD was primarily derived from a Cochrane review last updated in May 2009. 58 Th is systematic review evaluated the evidence from RCTs regarding treatment eff ects of infl uenza vaccination in subjects with COPD, including exacerbation rates, hospitalizations, mortality, lung function, and adverse eff ects. 58 Eleven studies were included in this systematic, evidence-based review, with six specifi cally performed in patients with COPD and two evaluating exacerbation rates using inactivated virus vaccination. 59 , 60 Th ese studies defi ned COPD minimally by specifi ed COPD clinical diagnosis and measured exacerbations determined clinically without rigorous or adjudicated defi nitions. In a pooled analysis across 180 subjects, inactivated infl uenza vaccine in patients with COPD resulted in a signifi cant reduction in the total number of exacerbations per vaccinated subject compared with those who received placebo (weighted mean diff erence [WMD], 2 0.37; 95% CI, 2 0.64 to 2 0.11; P 5 .006). Th e eff ect was further to occur only aft er 3 to 4 weeks, defi ned as late exacerbations (WMD, 2 0.39; 95% CI, 2 0.61 to 2 0.18; P 5 .0004). Both studies found a reduction in infl uenza-related respiratory infections (WMD, 0.19; 95% CI, 0.07-0.48; P 5 .0005).
Additional analyses in the Cochrane review 58 of other secondary outcomes found no effect on reduced hospitalization (OR, 0.33; 95% CI, 0.09-1.24; P 5 .52).
Analyses of a broader pool of patients with COPD and in elderly patients in general (only a minority of whom had COPD) found a signifi cant increase in the occurrence of local adverse reactions with vaccines , but the eff ects were generally mild and transient. Th ere was no evidence of an effect of intranasal live attenuated virus when added to an inactivated intramuscular vaccination. Th e studies were reported to be too small to have detected any eff ect on mortality.
In patients with COPD, we recommend administering the infl uenza vaccine annually to prevent acute exacerbations of COPD (Grade 1B).
Underlying Values and Preferences:
Th is recommendation places high value on the benefi ts of infl uenza vaccination for general health, the low risk of side eff ects, and the existing guidelines that recommend it for patients with COPD. Although the eff ect and evidence are moderate for the prevention of acute exacerbations of COPD, multiple bodies, including the CDC and WHO, recommend the use of a yearly infl uenza vaccine for all adults, including those with COPD. 61 , 62 by ameliorating the annual decline in lung function, 63 reducing cough and sputum production, 64 improving health-related quality of life, and reducing COPD exacerbations. Exacerbation frequency and active smoking may independently result in lung function decline. 65 Smoking cessation attempts may be diffi cult and frequently unsuccessful for patients with COPD who have prolonged exposure to tobacco smoke. 66 , 67 An eff ective smoking cessation program should address the behavioral, physiologic, and psychologic consequences of smoking; be cognizant of prior unsuccessful quit attempts; and target high-risk smokers.
Smoking cessation programs that range from simple strategies to intensive, multicomponent programs have been tested in patients with COPD. Th ese programs may comprise acknowledging current smoking followed by advice to quit, pharmacologic therapies (nicotine replacement therapy, antidepressants, nicotine receptor modifi er therapy), or counseling (in-person or telephone counseling). Th ese strategies have been used alone or in combination with varying success. Smoking cessation rates ranging from 8.8% to 34.5% have been reported and vary according to the strategy implemented, such as low-intensity counseling vs combination strategies that include psychosocial and pharmacologic interventions. 68 Most authors recommend a combination of pharmacologic and behavioral strategies for smokers with COPD. 68 -70 We identifi ed two observational evaluations of tobacco cessation eff ects on COPD exacerbations and two RCTs that were limited by quality and bias. 3. In patients with COPD, we suggest including smoking cessation counseling and treatment using best practices as a component of a comprehensive clinical strategy to prevent acute exacerbations of COPD (Grade 2C).
Th is recommendation places high value on the benefi ts of smoking cessation for all individuals. In particular, it is the only evidencebased intervention that improves COPD prognosis by mitigating lung function decline and reduces symptoms. Although the eff ect and evidence for smoking cessation in the prevention of acute exacerbations of COPD are low, evidence supports smoking cessation for many reasons. Among general health benefi ts, smoking cessation in patients with mild COPD who produce cough and phlegm leads to substantial symptom reduction in the fi rst year, with less lung function decline and fewer symptoms upon sustained cessation as well as leads to a decreased risk for infections such as pneumonia, which has been associated with cigarette smoking. Th e benefi t from smoking cessation outweighs the risks, and a myriad of strategies have been summarized by other guidelines and reviews. In general, eff ective smoking cessation programs include behavioral, physiologic, and psychologic components comprising an acknowledgment of current smoking followed by advice to quit, pharmacologic therapies (nicotine replacement therapy, antidepressants, nicotine receptor modifi er therapy), and counseling (in-person or telephone counseling) with cessation rates ranging from 8.8% to 34.5%. Smoking cessation that includes counseling and pharmacologic interventions are cost-eff ective.
Pulmonary Rehabilitation: Pulmonary rehabilitation has been recently defi ned as "a comprehensive intervention based on exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors. " 76 Th e benefi ts of pulmonary rehabilitation in patients with COPD are considerable, 76 -78 and rehabilitation has been shown to be the most effective therapeutic strategy to improve shortness of breath, health-related quality of life, and exercise tolerance. 79 , 80 Pulmonary rehabilitation is a prominent component of integrated COPD care 81 and is considered a standard-of-care intervention for individuals with COPD who remain symptomatic despite optimal bronchodilator therapy. 37 , 77 , 78 For this analysis, we assumed that an all-cause hospitalization refl ected a COPD-specifi c hospitalization. In a pooled analysis across 623 patients with COPD from all nine studies, 82 -90 pulmonary rehabilitation resulted in a signifi cant reduction in hospitalizations compared with conventional care (OR, 0.45; 95% CI, 0.22-0.91; P 5 .03).
Overall, the quality of evidence was rated low to very low due to risk of bias, inconsistency, and imprecision. Minimal harms were noted with participation in rehabilitation, with no serious adverse events reported. Considerable heterogeneity was observed between studies, with three of the nine showing a signifi cant reduction in hospitalizations following rehabilitation ( P 5 .03, I 2 5 52%). In an attempt to examine study heterogeneity, the studies were further categorized based on whether pulmonary rehabilitation was given immediately (ie, , 1 month) following a recent COPD hospitalization (unstable state or recovery phase) or in patients with stable disease. In the studies that examined the eff ect of pulmonary rehabilitation given immediately after a COPD hospitalization, the data show a reduction in COPD rehospitalizations following rehabilitation 82 -84 , 87 , 88 (OR, 0.24; 95% CI, 0.07-0.88; P 5 .03). Th ese fi ndings are consistent with an earlier Cochrane review by Puhan et al. 91 Of note, grade 1C was given because the studies examining pulmonary rehabilitation immediately aft er an acute exacerbation were judged to be of low or very-low quality, and signifi cant heterogeneity was observed between studies ( P 5 .008, I 2 5 71%).
In the four studies examining patients without a recent history of exacerbation (stable state), pulmonary rehabilitation consistently did not reduce COPD hospitalizations (OR, 0.79; 95% CI, 0.42-1.5; P 5 .47). 85 , 86 , 89 , 90 However, as previously mentioned, among patients with a recent exacerbation ( Յ 4 weeks from prior hospitalization), pulmonary rehabilitation has shown benefi t in reducing COPD hospitalizations, adding to the growing literature detailing the considerable patient benefi ts from pulmonary rehabilitation and supporting earlier statements advocating for greater access to pulmonary rehabilitation for patients with COPD. 76 , 77 Th e recommendation would be strengthened by consistent, high-quality, large RCTs that specifi cally track both acute exacerbations and exacerbation-related hospitalizations.
4. In patients with moderate, severe, or very severe COPD who have had a recent exacerbation (ie, Յ 4 weeks), we recommend pulmonary rehabilitation to prevent acute exacerbations of COPD (Grade 1C).
Th e pulmonary rehabilitation recommendations place high value on pulmonary rehabilitation reducing the risk of hospitalizations in patients with COPD who have had a recent COPD exacerbation (ie, Յ 4 weeks posthospitalization).
Although it has been well established that pulmonary rehabilitation improves quality of life, exercise tolerance, and dyspnea, these recommendations do not support pulmonary rehabilitation for the prevention of rehospitalizations in patients with COPD greater than 4 weeks aft er a recent hospitalization.
5.
In patients with moderate, severe, or very severe COPD who have had an exacerbation greater than the past 4 weeks, we do not suggest pulmonary rehabilitation to prevent acute exacerbations of COPD (Grade 2B).
Underlying Values and Preferences:
Th e pulmonary rehabilitation recommendations place high value on pulmonary rehabilitation reducing the risk of hospitalizations in patients with COPD who have had a recent COPD exacerbation (ie, Յ 4 weeks posthospitalization ) . Although it has been well established that pulmonary rehabilitation improves quality of life, exercise tolerance, and dyspnea, these recommendations do not support pulmonary rehabilitation for the prevention of rehospitalizations in patients with COPD greater than 4 weeks aft er a recent hospitalization.
Education, Action Plans, and Case Management:
Education, action plans, and case management are interventions that directly relate to the tenets of the Chronic Care Model. 92 Th ey focus on enabling patients to be knowledgeable about COPD, to have the necessary skills to manage their chronic disease, and to be motivated to take an active part in their health care in partnership with an experienced and engaged health-care team. Th ere is no consensus on the defi nition of education, action plans, and case management in COPD care. We defi ned education as formal delivery of information on topics related to COPD with the aim of improving the knowledge and understanding of COPD. Patient education was categorized as self-management education (eg, education aiming at patient self-management). An
action plan was defi ned as a written plan produced for the purpose of patient self-management of COPD exacerbations. Case management was defi ned as "a collaborative process of assessment, planning, facilitation, care coordination, evaluation, and advocacy for options and services to meet an individual's and family's comprehensive health needs through communication and available resources to promote quality, cost-eff ective outcomes. " 93 In this review, case management was identifi ed as structured follow-up, communication, or both with a health-care professional with a particular focus on changes in the patient's signs and symptoms; advice on appropriate interventions; referral to physicians; and recommendations for the initiation of therapy to prevent or reduce the risk of a serious AECOPD. Th e communication could be in person or through telephone or other teletechnology but did not include biomonitoring with data transferred over teletechnology.
This systematic review was completed before the 2014 Cochrane review on self-management for patients with COPD by Zwerink et al 94 and differs from that review in several important ways. Zwerink et al 94 searched the literature from 1994 to 2011, whereas the current literature review was not limited by publication date. The Cochrane review did not focus specifically on prevention of acute exacerbations of COPD and used a broad defi nition of self-management that included smoking cessation, self-recognition, and self-treatment of acute exacerbations of COPD; exercise and physical activity; action plans; and advice on diet, medication, and coping with dyspnea. In the present review, we chose to examine the eff ects of many of these interventions separately because these interventions oft en are delivered separately in current clinical practice . There is lack of data to recommend education alone to prevent COPD exacerbations. Only one study was conducted in a single hospital with a small sample size. Furthermore, the lack of information on the implementation of the patient education limits the ability of other investigators to replicate this intervention.
6. In patients with COPD, we suggest that education alone should not be used for prevention of acute exacerbations of COPD (Ungraded Consensus-Based Statement).
Underlying Values and Preferences:
Th is recommendation places high value on reducing hospitalizations for COPD exacerbations, as these are associated with increased morbidity and mortality. A lower value was placed on the motivational educational intervention because it is labor intensive compared with traditional education techniques.
Case Management Alone: One RCT 96 investigated the benefi ts of a 1-year period of case management alone on health-care use, which was a prespecifi ed secondary outcome of the study. Th e method of measuring ED visits, hospital admissions, and number of hospital days was not specifi ed. In this study, 122 patients who had been receiving long-term oxygen therapy for at least 6 months and who had a mean FEV 1 of 28% predicted were randomly assigned to an intervention or a usual-care group. Th e intervention combined home care management and easy access to hospital resources. It included a monthly telephone call and a home visit every 3 months as well as a rapid response to patient requests for assistance with respiratory issues over the 1-year study period. Th e intervention was associated with a highly signifi cant reduction in the number of hospitalizations (intervention group, 0. Although the intervention resulted in a statistically significant reduction in ED visits, hospitalizations, and hospitalization days, this evidence was from one study with a high risk of bias. Th erefore, because of the lack of suffi cient evidence for a graded recommendation, there is uncertainty about the eff ect of case management alone to prevent acute exacerbations of COPD.
7.
In patients with COPD, we suggest that case management alone should not be used for prevention of acute exacerbations of COPD (Ungraded ConsensusBased Statement).
Underlying Values and Preferences:
Th is recommendation places high value on reducing hospitalizations for COPD exacerbations, as these are associated with increased morbidity and mortality. A lower value was placed on the lack of change in quality of life in either group because this information was present for only a small proportion of the entire sample.
Education and Case Management (Without Action Plan):
Th ree studies 97 -99 met our inclusion criteria and assessed changes in hospitalizations, although not always as the primary outcome measure. None of these studies included an action plan in the intervention. Other outcome measures included visits to the physician's offi ce, clinic, or ED. Two studies 97 , 99 reported a decrease in hospitalizations in the intervention group, whereas the other found no diff erence between groups. 98 Th e data from two studies 97 , 98 were combined in a meta-analysis to assess the eff ect on hospitalizations. Th e results demonstrated no statistically signifi cant diff erences between groups. Aft er a 6-month follow-up period, Lainscak et al 97 reported a 14% hospitalization rate for the intervention group vs 31% for the control group, whereas Smith et al 98 reported that 70% of participants in the intervention group and 55% in the control group had one or more respiratory-related hospitalization. Th e pooled OR was 0.82 (95% CI, 0.17-3.99), with significant heterogeneity between studies ( P 5 .003, I 2 5 89%). Th e study by Soler et al 99 reported a signifi cant decrease in hospitalizations. Smith et al reported no impact of education and case management on hospitalizations, hospital length of stay, or ED visits; however, these results must be viewed with caution because the sample size was small and the dropout rate high and the data were missing in one-third of the study participants.
Heterogeneity in participant characteristics and study methodology aff ected our conclusion about the eff ect of education and case management on exacerbations. Although patients in all three studies had moderate to severe disease, their exacerbation histories diff ered. Th e studies by Lainscak et al 97 101 Th e number of events or the event rates were low in the four studies. Th e data from all studies were combined in separate meta-analyses to assess the eff ect of education combined with an action plan on ED visits and hospitalizations. Th ese studies demonstrated no eff ect on mean ED visits, mean hospitalizations, or hospitalization rates. Gallefoss 100 and Wood-Baker et al 103 also assessed the impact of the intervention on general practitioner visits. Gallefoss 100 reported that the intervention reduced the number of nonacute general practitioner visits, but there was no difference in the number of acute care visits. Wood-Baker et al 103 reported no diff erences between the groups in general practitioner visits. None of the studies reported any adverse events related to the intervention. Th e risk of bias was rated serious to very serious in all the studies.
Underlying Values and Preferences:
Education and Action Plan and Case Management:
We identifi ed 16 studies that met our inclusion criteria. Twelve presented original data that assessed the eff ect of education combined with a written action plan and individualized case management on hospital admissions and ED visits. Th e results of eight studies 104 -111 were combined in a meta-analysis to assess the eff ect of the intervention on hospitalizations. Four of these studies 104 , 107 -109 provided data for a meta-analysis of the eff ect of the intervention on ED visits. An additional four studies 112 -115 addressed outcomes of interest but could not be included in the meta-analyses.
Six studies 104 -106 , 109 , 114 , 115 specifically recruited participants with a history of exacerbations. Two studies 114 , 115 measured diff erences in all-cause hospitalizations and ED visits, whereas the other studies focused on acute exacerbations of COPD. Seven studies included in the meta-analysis reported the eff ect of a 12-month intervention on hospitalizations, 104 -109 , 111 and one study assessed a 6-month intervention. 110 In the meta-analysis assessing hospitalizations, Th e study by Fan et al, 106 a large, multisite study conducted in the Veterans Administration system, was stopped early due to excess mortality in the intervention group. At study termination, 426 individuals had been randomized to the usual-care or intervention group. Th ere was no diff erence in COPD-related exacerbations over the mean follow-up period of 250 days, but there were 28 deaths in the intervention group compared with 10 in the usual-care group. Deaths due to COPD accounted for the largest diff erence between the groups. Despite careful analysis, the authors were not able to explain the diff erence in mortality between the groups.
Comparison with large studies with similar interventions 104 , 109 did not help to explain the higher mortality in the case management group. Th ese unexpected results demonstrate that we do not yet fully understand the eff ects of this type of intervention.
10.
For patients with COPD, we suggest education with a written action plan and case management for the prevention of severe acute exacerbations of COPD as assessed by a decrease in hospitalizations and ED visits (Grade 2B).
Underlying Values and Preferences:
Th is recommendation places high value on reducing COPD-related hospitalizations, as these are associated with increased morbidity and mortality. Hospitalizations were believed to best refl ect exacerbations because increased physician visits or increased medication use could be a result of the intervention to prevent an exacerbation. High value was also placed on changes in individuals with a history of exacerbations and on outcomes that specifi cally identifi ed COPD-related hospitalizations. Th e recommendation refl ects the fact that one study reported increased mortality in the intervention group. Although we do not know the reason for increased mortality in this one study, patients with underlying severe disease and clinical instability need close attention and careful follow-up. Th is point emphasizes that a specially trained staff is required to supervise this intervention and that patient selection must be individualized.
Telemonitoring: Information and communications technologies have rapidly developed the potential to contribute to the delivery of accessible, cost-eff ective, high-quality health-care services, although evaluation of these services is still at an early stage. 116 Although there is no single defi nitive defi nition of telemedicine, the American Telemedicine Association defi nes it as "the use of medical information exchanged from one site to another via electronic communications to improve a patient's clinical health status. " 117 "Telemedicine" is a broad term that encompasses a wide range of services, including video conferencing; e-health, such as patient portals; transmission of still images; continuing medical education; consumer-focused wireless applications; and remote monitoring of vital signs. 117 Given the range of telemedicine options, we have restricted our review to studies dealing with telemonitoring to provide care for patients at risk for acute exacerbations of COPD. We defi ned telemonitoring as comprising the following elements: (1) electronic transfer of self-report or biometric data (eg, oxygen saturation, pulse rate, BP) over a distance; (2) use of a device located in the patient's home or on his or her person (mobile device); and (3) personalized feedback from a health-care professional who exercises his or her skills and judgment in the provision of tailored advice to the patient or automated feedback based on a predetermined algorithm.
Our recommendation is based on three RCTs 118 -120 from one systematic review 121 that met our defi nition and 18 additional RCTs. 122 -139 Of these, only six studies 127 , 130 -134 in 707 subjects were poolable, although we did take into account the fi ndings of studies not included in the meta-analysis in making our recommendation. Importantly, there was substantial variability in the telemonitoring interventions and equipment used, which included recording and electronic transmission of vital signs (spirometry, pulse oximetry, heart rate, and BP) 130 , 131 ; a technology platform for delivery of education and transmission of pedometer results 131 ; a hand-held monitor, self-reported symptoms, and manually entered temperature and oximetry 132 ; sensor-containing wristbands for heart rate, physical activity, near body temperature, and galvanic skin response; a commercial oximeter and cell phone coupled with a wristband 134 ; self-report data (EXACT-PRO [Exacerbations of Chronic Pulmonary Disease Tool Patient-Oriented Outcome] questionnaire) transmitted through cell phones; and automated alert calls based on winter weather conditions. 127 Th e variability among the telemonitoring applications precludes accurate comparison between studies.
A review by Wootton 140 noted that the majority of RCTs on telemedicine for chronic disease management reported positive eff ects, raising the possibility that a publication bias exists favoring only positive results. Wootton further suggested that understanding the true eff ects of any intervention to improve chronic illness care will require interventions lasting years rather than weeks or months. Although telemonitoring holds promise for COPD management, there is no evidence at this time that telemonitoring signifi cantly reduces acute exacerbations of COPD, and in many countries, it is too expensive.
For patients with COPD, we suggest that telemonitoring compared with usual care does not prevent acute exacerbations of COPD, as assessed by decreases in emergency room visits, exacerbations, or hospitalizations over a 12-month period (Grade 2C).
Underlying Values and Preferences:
Th ere is insuffi cient evidence at this time to support the contention that telemonitoring prevents COPD exacerbations.
PICO 2: Does Maintenance Inhaled Therapy Prevent/Decrease Acute Exacerbations of COPD?
An extensive amount of data is available regarding the eff ects of inhaled therapy on the treatment and prevention of acute exacerbations of COPD. To examine this area in a systematic fashion, we organized the analysis of the effi cacy of inhaled therapy to prevent COPD exacerbations into separate analyses of short-acting b 2 -agonists and short-acting muscarinic antagonists vs placebo and long-acting b 2 -agonists and long-acting muscarinic antagonists vs placebo with each other and in combination. Similarly, we compared inhaled corticosteroids with placebo and the combination of long-acting b 2 -agonists plus inhaled corticosteroids with placebo and vs long-acting muscarinic antagonists and the combination of all three inhaled agents with placebo to prevent COPD exacerbations ( Table 1 ) . Th e safety of this class of medications was evident. When all studies were pooled and analyzed, the rate of adverse events was similar between the long-acting b 2 -agonist and placebo arms (OR, 0.97; 95% CI, 0.83-1.14). Th e long-acting b 2 -agonist arm did not affect mortality (OR, 0.90; 95% CI, 0.75-1.08). In summary, patients with moderate to severe COPD had reduced rates of exacerbations (both moderate and severe) with a long-acting b 2 -agonist vs placebo. Benefi ts in other aspects of COPD management were demonstrated, with strong safety data.
Long-Acting Bronchodilators Compared With Placebo
12.
In patients with moderate to severe COPD, we recommend the use of long-acting b 2 -agonist compared with placebo to prevent moderate to severe acute exacerbations of COPD (Grade 1B).
Underlying Values and Preferences:
Th is recommendation places high value on long-acting b 2 -agonist therapy reducing the risk of acute exacerbations of COPD, both moderate (required course of oral steroids, antibiotics, or both) and severe (required hospitalization), together with the comparative benefi t of long-acting b 2 -agonist therapy improving quality of life and lung function compared with placebo. This recommendation also acknowledges that there are no signifi cant diff erences in serious adverse events or incidence of mortality between long-acting b 2 -agonist therapy and placebo in this patient group.
Long-Acting Muscarinic Antagonists Compared
With Placebo: Tiotropium is an inhaled long-acting muscarinic antagonist used in the treatment of COPD.
Tiotropium inhibits the release of acetylcholine at the receptor level by binding to the M2-and M3-muscarinic receptors that line the airway. The resulting bronchodilation has improved outcomes, including quality of life, increased exercise capacity, and a reduction in exacerbations. 23 , 142 , 143 Furthermore, its safety has been reviewed in several analyses, all of which demonstrate an acceptable safety profi le. Until recently, tiotropium had only been delivered as a dry powder through the HandiHaler (Boehringer Ingelheim GmbH). Th e large majority of studies assessing the effi cacy of tiotropium involved the use of the dry powder inhaler in the treatment arm. Respimat (Boehringer Ingelheim GmbH) is a novel delivery system using a soft mist rather than a dry powder as the means of delivering tiotropium.
Th ere has been some concern regarding the safety of tiotropium delivered through Respimat 144 because studies have demonstrated an increase in associated mortality.
To address this question, a large RCT assessing the safety of tiotropium delivered through the Respimat system has recently been published, 145 and this will be further in this guideline.
A systematic review 146 . Both were not statistically signifi cant. Although this is reassuring, safety issues remain a concern with the Respimat system in secondary analysis of TIOSPIR data, especially in patients with renal disease (who were excluded from this study).
13. In patients with moderate to severe COPD, we recommend the use of a long-acting muscarinic antagonist compared with placebo to prevent moderate to severe acute exacerbations of COPD (Grade 1A).
Underlying Values and Preferences:
Th is recommendation places high value on long-acting muscarinic antagonists reducing the risk of acute exacerbations of COPD, both moderate (required course of oral steroids, antibiotics, or both) and severe (required hospitalization), together with the comparative benefi t of a long-acting muscarinic antagonist improving quality of life and lung function compared with placebo. Although pooled analyses show a reduction in COPD hospitalization with the use of a long-acting muscarinic antagonist compared with placebo, it does not reach statistical signifi cance for all-cause hospitalization. Th is recommendation also acknowledges that there are no signifi cant diff erences in serious adverse events or incidence of mortality between long-acting muscarinic antagonists and placebo in this patient group.
Long-Acting Muscarinic Antagonists Compared With
Long-Acting b 2 -Agonists: Pharmacologic therapy for COPD is implemented in a stepwise fashion. 142 , 147 Patients should be started initially on short-acting bronchodilators, and if symptoms persist, introduction of long-acting bronchodilators is recommended. Th e two classes of long-acting agents used in the treatment of COPD are long-acting muscarinic antagonists and long-acting b 2 -agonists. Both classes have independent mechanisms of action, producing a bronchodilator effect resulting in improved symptoms, quality of life, and exercise tolerance. 148 -150 In addition, each class has been shown to reduce the rate of acute exacerbations. 23 Th e authors recognized that the largest and longest study comparing tiotropium to salmeterol had a statistically signifi cant diff erence in the rate of exacerbation. 153 All the other studies reviewed did not demonstrate that tiotropium was signifi cantly better at preventing exacerbations than long-acting b 2 -agonists, which one must keep in mind while interpreting the recommendation. Furthermore, a large majority of patients were using inhaled corticosteroids during the study. Th e impact that this may have on the exacerbation rate is diffi cult to determine.
14. In patients with moderate to severe COPD, we recommend the use of long-acting muscarinic antagonists compared with long-acting b 2 -agonist to prevent moderate to severe acute exacerbations of COPD (Grade 1C).
Underlying Values and Preferences:
Th is recommendation places high value on long-acting muscarinic antagonists reducing the risk of acute exacerbations of COPD, both moderate (required course of oral steroids, antibiotics, or both) and severe (required hospitalization), together with the comparative benefi t of long-acting muscarinic antagonists having a lower rate of nonfatal serious adverse events compared with long-acting b 2 -agonists. Th is comparative benefi t may not apply with the new ultralong-acting b 2 -agonists that are a once-daily medication. Although pooled analyses show a reduction in COPD hospitalization with the use of a long-acting muscarinic antagonist compared with placebo, it does not reach statistical signifi cance for all-cause hospitalization. A lower value was placed on the lack of statistically signifi cant diff erences in changes in lung function, quality of life, and patient symptoms between the two drug groups.
Short-Acting Muscarinic Antagonist Compared With
Short-Acting b 2 -Agonist Monotherapy: Based on the available data, comparing treatment with short-acting b 2 -agonist monotherapy with ipratropium alone (shortacting muscarinic antagonist) for 1 to 3 months resulted in no signifi cant improvement in postbronchodilator FEV 1 measurement, but there was a small benefit in prebronchodilator FEV 1 of borderline statistical significance. Th ere was a small increase in prebron chodilator FVC and a postbronchodilator increase in the FVC area under the curve over 8 h, and this approached statistical signifi cance. Th ese data suggest that the benefi cial eff ects of a short-acting muscarinic antagonist over shortacting b 2 -agonist are small in terms of lung function. 154 -160 Th ere was no study evaluating exacerbation as a primary end point. However, four studies enrolling 1,218 patients with a serious risk of bias and overall moderate quality of evidence examined the number of subjects who had to add or increase systemic oral corticosteroids, which could be interpreted as a surrogate marker for exacerbations. 157 , 161 -163 Meta-analysis of the four studies indicated that signifi cantly fewer subjects receiving short-acting muscarinic antagonist therapy added or increased use of oral steroids compared with those receiving short-acting b 2 -agonist therapy (OR, 0.52; 95% CI, 0.37-0.74). Th is would give a number needed to treat of 15 patients treated with short-acting muscarinic antagonist therapy compared with 28 patients treated with short-acting b 2 -agonist therapy to prevent the need for oral steroids.
Th erefore, this treatment comparison receives a grade 2C recommendation based on the body of reported evidence. Th e grade 2C categorization is weak, with low-or very-low-quality evidence and uncertainty in the estimates of the benefi ts, risks, and burdens, all of which are closely balanced. However, there is evidence of benefi t for at least one critical outcome (addition or increase in the use of oral steroids) that may be considered a surrogate marker of a moderate exacerbation. Higher-quality research may have an important impact on the confi dence of estimated eff ect in the future. Patient preference and cost should be taken into consideration. Future studies could incorporate measures of health-care use and be of longer duration to capture the eff ects on exacerbation rates.
In patients with moderate to severe COPD, we suggest the use of a short-acting muscarinic antagonist compared with short-acting b 2 -agonist monotherapy to prevent acute mild-moderate exacerbations of COPD (Grade 2C).
Underlying Values and Preferences:
Th is recommendation places value on a short-acting muscarinic antagonist reducing the risk of acute exacerbations of COPD together with the comparative benefi t of a short-acting muscarinic antagonist improving quality of life and lung function compared with short-acting b 2 -agonist monotherapy. No data favor one therapy over the other in terms of COPD hospitalizations. Th is recommendation also acknowledges that medication-related adverse events were fewer in the short-acting muscarinic antagonist than in the short-acting b 2 -agonist group.
Short-Acting Muscarinic Antagonist Plus ShortActing b 2 -Agonist Compared With Short-Acting b 2 -Agonist:
Stepwise pharmacologic therapy, particularly when two diff erent agents with diff erent mechanisms of action are used, is the standard therapy for asthma and COPD care in all guidelines. Long-term combination therapy of a short-acting muscarinic antagonist and a short-acting b 2 -agonist over 12 weeks with ipratropium plus a short-acting b 2 -agonist is associated with some clinically meaningful postbronchodilator outcomes compared with b 2 -agonist treatment alone, but these outcomes were not refl ected in subjective improvements in quality of life or symptom scores. 154 Th e evidence for this combined therapy vs monotherapy using short-acting bronchodilators to reduce exacerbations is either weak or lacking.
Th ere has been only one study with exacerbation as an end point, and that favored the combination (ipratropium plus short-acting b 2 -agonist). 164 Th e study had serious bias and inconsistency. Th e evidence, therefore, was rated as overall low quality. Five additional studies enrolling 1,591 patients from 42 to 85 days recorded the addition of or increase in oral steroids as an end point. 157 , 160 -167 Th ese studies in aggregate had no serious inconsistencies in quality assessment and an overall moderate quality of evidence. We have given this recommendation a grade 2B, which is weak with moderate-quality evidence because of the long history of safety and clinical guideline data formulated throughout the years.
Th e patient's preference is an important factor that requires consideration in using these agents, and generally, these agents are fi rst line because of their safety profi le and ease of use. Future studies should be of longer duration to more robustly capture the eff ects of these agents on exacerbation rates and incorporate outcomes that measure health-care use.
16. In patients with moderate to severe COPD, we suggest the use of short-acting muscarinic antagonist plus short-acting b 2 -agonist compared with shortacting b 2 -agonist alone to prevent acute moderate exacerbations of COPD (Grade 2B).
Underlying Values and Preferences:
Th is recommendation places value on a short-acting muscarinic antagonist plus a short-acting b 2 -agonist reducing the risk of acute exacerbations of COPD together with the comparative small benefi ts of a short-acting muscarinic antagonist plus a short-acting b 2 -agonist improving quality of life, exercise tolerance, and lung function compared with a short-acting b 2 -agonist alone. Th is recommendation also acknowledges that there are no signifi cant diff erences in serious adverse events with the use of a short-acting muscarinic antagonist plus a short-acting b 2 -agonist vs a short-acting b 2 -agonist alone.
Short-Acting Muscarinic Antagonists Compared With
Long-Acting b 2 -Agonist Monotherapy: Th e primary classes of bronchodilators used in the treatment of COPD have both short-acting and long-acting formulations. Current guidelines suggest that patients with moderate to severe COPD use the short-acting formulations for rescue and the long-acting bronchodilators as maintenance therapy. 142 , 147 Th is recommendation is based on several advantages the long-acting formulations have over the short-acting agents, including
sustained bronchodilation, improved quality of life, and improved compliance. 168 -170 A systematic review comparing short-acting muscarinic antagonist (ipratropium) monotherapy vs long-acting b 2 -agonist therapy assessed change in lung function, quality of life, symptom scores, and exacerbation rates. 154 Th is analysis included four studies comparing ipratropium 42 m g with salmeterol 50 m g and placebo. As well, one study comparing ipratropium 80 m g tid with formoterol 18 m g bid and placebo and another comparing ipratropium 40 m g qid with formoterol 12 or 24 m g and placebo were included for analysis.
For the ipratropium vs salmeterol studies, there was no signifi cant diff erence in the patients experiencing one or more exacerbations (OR, 1.23; 95% CI, 0.84-1.80). Th e quality of evidence was low given inconsistency and imprecision. For the formoterol studies, there was no signifi cant diff erence in exacerbation rates, but values were not provided. Th e studies used in the systematic review had varying inclusion criteria, used unconventional dosing for both ipratropium and the long-acting b 2 -agonists, and did not provide clear defi nitions for exacerbations. Given the poor evidence addressing the question of ipratropium vs long-acting b 2 -agonists for the prevention of acute exacerbations, the current recommendation is made based on the known benefi ts of long-acting b 2 -agonists in patients with COPD. 141 17. In patients with moderate to severe COPD, we suggest the use of long-acting b 2 -agonist monotherapy compared with short-acting muscarinic antagonist monotherapy to prevent acute exacerbations of COPD (Grade 2C).
Underlying Values and Preferences:
Th is recommendation places value on long-acting b 2 -agonist therapy reducing the risk of acute exacerbations of COPD in patients treated with long-acting b 2 -agonist monotherapy over short-acting muscarinic antagonist monotherapy and the comparative value of long-acting b 2 -agonist monotherapy improving lung function, quality of life, and dyspnea scores compared with short-acting muscarinic antagonist monotherapy. No data favor one therapy over the other in terms of COPD hospitalizations. Th is recommendation also acknowledges that there are no signifi cant diff erences in serious adverse events with the use of long-acting b 2 -agonist monotherapy over shortacting muscarinic antagonist monotherapy.
Long-Acting Muscarinic Antagonist Compared With
Short-Acting Muscarinic Antagonist: Th e airfl ow obstruction associated with moderate to severe COPD results in exercise limitation, poor quality of life, and a predisposition to exacerbations. Bronchodilators, both short-acting and long-acting, play an important role in helping patients with COPD to cope with the disease by improving many of the physiologic limitations that develop with activity in these patients. 148 , 150 , 171 Inhaled muscarinic antagonists (or anticholinergics) have long been recognized as an important pharmacologic class of bronchodilators that result in improved quality of life, symptom limitation, and reduced rate of exacerbations. 146 , 172 Ipratropium is a short-acting muscarinic antagonist that nonspecifi cally binds to airway muscarinic receptors. Tiotropium is a long-acting muscarinic antagonist that selectively binds to M1-and M3-muscarinic receptors in the airway. Until recently, it has been the only inhaled muscarinic antagonist available for treating COPD. 142 , 147 Newer muscarinic antagonists are now available, including aclidinium bromide, glycopyrronium bromide, and umeclidinium bromide. Th e majority of studies involving these newer compounds compared effi cacy to either placebo or tiotropium and not to ipratropium. Furthermore, there is no meta-analysis comparing these compounds with ipratropium. Th us, for the question of the benefi t of a long-acting muscarinic antagonist vs shortacting muscarinic antagonist for the prevention of an exacerbation, the evidence for tiotropium vs ipratropium was assessed.
A recent systematic review compared tiotropium and ipratropium in the treatment of stable COPD. 173 Th e review included two studies enrolling 1,073 patients. One study randomized patients to tiotropium 18 m g delivered by HandiHaler, and the other used tiotropium 5 and 10 m g delivered by the Respimat system. Both studies used an ipratropium metered-dose inhaler as the comparator arm. In both studies, the rates of acute exacerbations and COPD hospitalizations were secondary outcomes. Tiotropium was superior to ipratropium in exacerbation prevention (OR, 0.71; 95% CI, 0.52-0.95). Th e quality of the evidence was high, and there was no risk of bias. Furthermore, use of tiotropium resulted in a lower rate of hospitalization due to exacerbation compared with ipratropium (OR, 0.56; 95% CI, 0.31-0.99). Th e quality of evidence for this outcome was also deemed to be high with no risk of bias. Th e superiority of tiotropium over ipratropium was also seen in trough FEV 1 values and quality of life. Th ere were insuffi cient data available to recommend one delivery device for tiotropium over another; however, no harm was demonstrated in the study using the Respimat delivery system.
Th e authors supported the use of tiotropium over ipratropium in the treatment of stable COPD because physiologic and clinical benefi ts, including reduced rates of exacerbation, were seen in the patients randomized to tiotropium. Th eir conclusion supports current clinical thinking and guideline recommendations. 142 , 147 In addition to a clinical benefi t, the once-daily dosing of tiotropium is associated with improved compliance compared with ipratropium. 170 Th e safety of the Respimat system used to deliver tiotropium remains controversial. 144 In this review, no conclusions could be made regarding the superiority of one delivery device over the other, and no safety concerns were noted. Concern regarding safety of tiotropium delivered through the Respimat system has been well documented. A recent multicenter international RCT demonstrated the safety of the Respimat delivery system for tiotropium vs HandiHaler. 145 However, controversy still remains because a secondary analysis of the RCT data suggests that specifi c patient populations may be at risk for adverse events or higher mortality. 174 -176 18. In patients with moderate to severe COPD, we recommend the use of a long-acting muscarinic antagonist compared with a short-acting muscarinic antagonist to prevent acute moderate to severe exacerbations of COPD (Grade 1A).
Underlying Values and Preferences:
Th is recommendation places high value on a long-acting muscarinic antagonist reducing the risk of acute exacerbations of COPD, both moderate (required course of oral steroids, antibiotics, or both) and severe (required hospitalization), together with the comparative benefi t of a longacting muscarinic antagonist improving quality of life and lung function compared with a short-acting muscarinic antagonist. Th is recommendation also acknowledges that there were fewer nonfatal serious adverse events in subjects treated with a long-acting muscarinic antagonist than in those treated with a short-acting muscarinic antagonist.
Short-Acting Muscarinic Antagonist Plus LongActing b 2 -Agonist Compared With Long-Acting b 2 -Agonist Monotherapy: Th e natural progression of COPD results in increased symptoms, a decline in quality of life, and an increased risk of exacerbations. As the disease progresses and the patient's needs change, current guidelines recommend add-on pharmacotherapy to address the symptoms. One option is the addition of regular ipratropium, a short-acting muscarinic antagonist, to a long-acting b 2 -agonist. Using bronchodilators that target diff erent receptors may improve clinical symptoms and, therefore, may prevent exacerbations. Although this combination may be viewed as unique, some studies assessed its eff ectiveness in patients with COPD. A meta-analysis reviewed the available data comparing ipratropium plus long-acting b 2 -agonist vs long-acting b 2 -agonist alone in the treatment of stable COPD. 154 Th is analysis highlighted that few studies (two unpublished and one published) exist on this therapeutic strategy for COPD. Th e one published study examined the impact that the ipratropium and long-acting b 2 -agonist combination has on the prevention of exacerbations. Th e 12-week study enrolled 94 patients who were randomized to ipratropium plus salmeterol vs salmeterol alone. Patients were allowed to use a short-acting b 2 -agonist for rescue. The combination therapy demonstrated a lower rate of exacerbations but was not statistically signifi cant (OR, 0.49; 95% CI, 0.17-1.40).
However, there was a low rate of exacerbation in both groups and improvements in lung function and quality of life with the combination vs lone long-acting b 2 -agonist therapy. The long-acting b 2 -agonist used in this study was salmeterol, and currently, no other published studies used other long-acting b 2 -agonists in combination with ipratropium. Th e authors concluded that more studies are needed to examine this combination because of some suggestion of benefi t.
We recognize that with the development of new longacting b 2 -agonists and long-acting muscarinic antagonists to treat COPD, including the combination of long-acting b 2 -agonist and long-acting muscarinic antagonist in a single inhaler, the utility of ipratropium plus long-acting b 2 -agonist is limited, which may explain the limited number of studies examining this combination. However, availability of these novel therapies, especially in resource-limited settings, can aff ect one's approach to therapy. Th erefore, having multiple therapeutic options that may provide similar outcomes for a global population would be ideal. For the combination of ipratropium plus long-acting b 2 -agonist vs longacting b 2 -agonist alone for the prevention of acute exacerbations of COPD, a grade 2C recommendation favoring the combination is given. Th is is based on the demonstrated safety of this combination, the improvements in functional and quality-of-life measures, and an indication of benefi t in reducing the frequency of exacerbations. 
In patients
Underlying Values and Preferences:
Th is recommendation places value on the combination of short-acting muscarinic antagonist plus long-acting b 2 -agonist therapy reducing the risk of acute exacerbations of COPD compared with the use of long-acting b 2 -agonist therapy alone and the comparative value of short-acting muscarinic antagonist plus long-acting b 2 -agonist therapy improving lung function, quality of life, and dyspnea scores compared with long-acting b 2 -agonist monotherapy. No data favor one therapy over the other in terms of COPD hospitalizations. Th is recommendation also acknowledges that there are no signifi cant diff erences in serious adverse events with the combined use of shortacting muscarinic antagonist plus long-acting b 2 -agonist therapy vs long-acting b 2 -agonist therapy alone.
Inhaled Corticosteroids Compared With Placebo or
Other Monotherapy: Airway infl ammation plays an important role in the pathophysiology of COPD, 177 which has suggested a potential role for inhaled corticosteroids in the treatment of this disease and has led to their excessive use in clinical practice. 178 , 179 However, although inhaled corticosteroids have signifi cant eff ects in suppressing airway infl ammation in asthma, their antiinfl ammatory eff ects in COPD are debatable. 180 -182 Th e reported relative resistance to the antiinfl ammatory eff ects of corticosteroids observed in COPD may be attributed to oxidative stress from smoke exposure or from neutrophilic infl ammation. In vitro and in vivo evidence suggest that histone deacetylase 2 enzyme activity and expression are suppressed in patients with COPD, thus blunting the antiinfl ammatory eff ects of corticosteroids. 180 -185 Nevertheless, a meta-analysis of eight RCTs that used bronchial biopsy specimens and BAL fl uid to evaluate the eff ects of inhaled corticosteroids in stable COPD showed that inhaled corticosteroids reduce lymphocytic infl ammation in COPD. 186 Th ese fi ndings suggest that antiinfl ammatory eff ects of inhaled corticosteroids may be more pronounced in patients with predominant lymphocytic airway infl ammation.
Several short-and long-term studies (up to 3 years) evaluated the effi cacy and safety of inhaled corticosteroids when used in combination with inhaled longacting b 2 -agonists. 22 , 151 , 187 -199 In addition, several systematic reviews and meta-analyses have been published on the topic. 200 -204 Th ese studies evaluated several important outcomes, including lung function, mortality, exacerbations, health-related quality of life, and symptoms. Despite the plethora of studies, the precise role of role of inhaled corticosteroids in improving lung function and other patient outcomes in COPD is still controversial. Furthermore, predictors of response to inhaled corticosteroids in COPD have not been fully evaluated, and existing evidence is based on few studies in the general COPD population. Because the use of inhaled corticosteroids may be associated with potential local and systemic adverse eff ects, careful evaluation of the benefi t and risk ratio is essential.
Long-Term Eff ects of Inhaled Corticosteroids Compared
With Placebo: A systematic review evaluated the role of inhaled corticosteroids vs placebo in COPD by examining data from 55 primary studies enrolling 16,154 participants. 204 Long-term use of inhaled corticosteroids reduced the mean rate of exacerbations in those studies where pooling of data was possible (generic inverse variance analysis using the total exacerbations per patient per year and SE from each study: relative eff ect, 2 0.26 exacerbations/ patient/year [95% CI, 2 0.37 to 2 0.14; 2,586 participants]; moderate overall quality of evidence due to risk of bias by pooled means analysis: relative effect, 2 0.19 exacerbations/patient/year [95% CI, 2 0.30 to 2 0.08; 2,253 participants]; overall quality of evidence low due to risk of bias and inconsistency ). Response to inhaled corticosteroids was not predicted by oral steroid response, bronchodilator reversibility, or bronchial hyperresponsiveness in patients with COPD. Studies of , 1,000 m g beclomethasone dipropionate equivalents per day did not show a statistically signifi cant diff erence compared with placebo.
Th ere was an increased risk of oropharyngeal candidiasis (OR, 2.65; 95% CI, 2.03-3.46; 5,586 participants) and hoarseness. In the long-term studies, the rate of pneumonia was increased in the inhaled corticosteroid group compared with the placebo group in studies that reported pneumonia as an adverse event (OR, 1.56; 95% CI, 1.30-1.86; 6,235 participants). Th e long-term studies that measured bone eff ects generally showed no major eff ect on fractures and bone mineral density over 3 years.
Inhaled Corticosteroids Compared With Long-Acting b 2 -Agonists: Both long-acting b 2 -agonists and inhaled corticosteroids are used in the treatment of COPD. Although these treatments can sometimes be taken together, the value of the two individual components is unclear. To evaluate the effi cacy and safety of inhaled corticosteroids vs long-acting b 2 -agonists in COPD, a review examined data from seven randomized trials (5,997 participants) of good quality with a duration of 6 months to 3 years. 202 All the trials compared inhaled corticosteroid/long-acting b 2 -agonist combination inhalers with long-acting b 2 -agonist and inhaled corticosteroid as individual components.
Four studies (4,750 participants) reported exacerbation RRs between inhaled corticosteroid or long-acting b 2 -agonist and placebo or an inhaled corticosteroid/ long-acting b 2 -agonist combination. 22 , 151 , 190 , 199 Th e RR between inhaled corticosteroid and long-acting b 2 -agonist was not statistically signifi cant (0.96; 95% CI, 0.89-1.02), which suggests moderate overall quality of evidence due to risk of bias. Th ere was no statistically signifi cant diff erence in exacerbation RR between studies of 1 year and . 1 year of treatment ( x 2 5 0.11, degrees of freedom 5 1, P 5 .75). Two studies comparing fl uticasone with salmeterol reported the number of patients experiencing exacerbations requiring treatment with antibiotics, corticosteroids, or both or hospitalization during the treatment period (688 participants). 193 , 196 In these studies, although more patients on inhaled corticosteroids (136 of 351) experienced exacerbations than those on long-acting b 2 -agonists (115 of 337), there was no statistically signifi cant diff erence between the groups (OR, 1.22; 95% CI, 0.89-1.67).
Exacerbations leading to hospitalizations were only reported in a single trial with 3,093 participants. 151 A comparison of RRs showed no signifi cant diff erence in the risk of hospitalization due to exacerbation between fl uticasone and salmeterol (RR, 1.07; 95% CI, 0.91-1.26). Th e incidence of pneumonia was signifi cantly higher among patients on inhaled corticosteroids than on long-acting b 2 -agonists whether classifi ed as an adverse event (OR, 1.38; 95% CI, 1.10-1.73) or serious adverse event (OR, 1.48; 95% CI, 1.13-1.93).
Budesonide Compared With Formoterol or Fluticasone Compared With Salmeterol:
Four of the trials included in the aforementioned review evaluated fl uticasone and salmeterol monotherapy components, and the remaining three included budesonide and formoterol monotherapy components. 202 Th ere was no evidence of a class eff ect between the fl uticasone/salmeterol and budesonide/formoterol trials in a subgroup analysis ( x 2 5 1.57, degrees of freedom 5 1, P 5 .21).
In summary, there was no statistically signifi cant diff erences in the number of patients experiencing exacerbations (OR, 1.22; 95% CI, 0.89-1.67) or the rate of exacerbations per patient year (RR, 0.96; 95% CI, 0.89-1.02) between inhaled corticosteroids and longacting b 2 -agonists. Both inhaled corticosteroids and long-acting b 2 -agonists contribute to a decrease in exacerbation rates, but there is insuffi cient evidence to recommend maintenance inhaled corticosteroid therapy over maintenance long-acting b 2 -agonist therapy in preventing acute exacerbations of COPD. Although inhaled corticosteroid therapy may benefi t some patients with COPD, it also increases the risk of systemic adverse eff ects, including pneumonia. 17 , 142 , 147 Th e eff ect of combination therapy has proven benefi cial for lung function and health-related quality of life, but the eff ectiveness on exacerbations remains less clear. 219 , 220 In its most recent iteration, 142 the GOLD (Global Initiative for Chronic Obstructive Lung Disease) grades disease severity using the number of exacerbations as a risk categorization and recommends combination therapy for patients with two or more exacerbations (categories C and D). Exacerbations were also highlighted and specifi cally targeted for combination therapy in prior CTS practice guidelines. 147 Th e combination includes primarily an inhaled corticosteroid and a long-acting b 2 -agonist, although potential use of a long-acting muscarinic antagonist plus a long-acting b 2 -agonist is also recommended based primarily on consensus. In patients with more severe COPD (GOLD category D), triple therapy is considered appropriate.
Combination
Evidence for Combination Inhaled Corticosteroid/ Long-Acting b 2 -Agonist Compared With Single
Bronchodilator: Relatively few long-term studies have compared combination inhaled corticosteroid and long-acting b 2 -agonist with single drugs, with exacerbations as the main outcome. A Cochrane meta-analysis 220 found 14 studies that met these inclusion criteria, randomizing 11,794 patients with severe COPD. Th e review evaluated 10 studies assessing fl uticasone plus salmeterol and four studies assessing budesonide plus formoterol separately. Th e studies were well designed with a low risk of bias for randomization and blinding, but they had high rates of attrition, which reduced confi dence in the results for outcomes. Th e reviewers concluded that the combination inhaled corticosteroid/ long-acting b 2 -agonist therapy reduced the number of exacerbations but did not aff ect the rate of hospitalizations compared with long-acting b 2 -agonist therapy alone. Th e combination did result in better lung function, health-related quality of life, dyspnea, and reduced use of rescue medication, but the diff erences did not reach clinical signifi cance. Th ere was a 4% increased risk of pneumonia in the combination therapy group compared with the long-acting b 2 -agonist alone group. Th ere are no head-to-head comparisons of the newer combinations (once-a-day formulations) that provide fi rm recommendations regarding their use and indications. However, the studies of the once-a-day single delivery combination of inhaled corticosteroid and long-acting b 2 -agonist again show better lung function and less dyspnea and rescue medication use with a small eff ect on exacerbations and no eff ect on hospitalizations over bronchodilators alone. 191 , 221 Th ere are few data comparing triple therapy with double or single therapy. A systematic review compared the effi cacy of three therapeutic approaches: tiotropium plus long-acting b 2 -agonist (dual therapy), long-acting b 2 -agonist plus inhaled corticosteroid (combined therapy), and tiotropium plus inhaled corticosteroid plus longacting b 2 -agonist (triple therapy), each compared with tiotropium single therapy. 214 Twenty trials enrolling 6,803 patients were included in the review. Th e authors concluded that dual therapy improved lung function and health-related quality of life but failed to decrease exacerbation frequency compared with tiotropium monotherapy. Combined therapy also improved lung function, health-related quality of life, and dyspnea without a signifi cant impact on risk of exacerbations. Again, the authors observed an increased risk of adverse events in patients receiving this therapy. Triple therapy increased lung function and improved health-related quality of life (reaching minimally important clinical thresholds in both outcomes) and marginally improved risk for exacerbations. However, the authors still concluded that the data were insuffi cient to make strong recommendations.
In some of these studies, the responses or benefi ts in end points, such as lung function, health-related quality of life, and dyspnea, do not always parallel the observed responses in reducing acute exacerbations. Although the reasons for these occasional dissimilar responses are not clearly obvious, it appears reasonable to independently assess the specifi c impact of these interventions on reducing exacerbations. In the administration of treatment medication for COPD, the inhalation route has been favored for the past 30 years. Th is technique enables the drugs to act directly on the airways, provided that the inhalation device is used correctly. Although inhaled medications are not without adverse eff ects, they oft en are seen as having a better tolerability and safety profi le than oral medications. Some medications can only be administered orally. Selecting drugs that are orally administered depends on the type of drug and the patient. Furthermore, poor access to inhaled medications can be a problem in some countries. We chose to organize the review of oral therapy by the following categories: antibiotics, oral corticosteroids, phosphodiesterase inhibitors (rofl umilast, theophylline), mucolytic agents (N-acetylcysteine [NAC], erdosteine, and carbocysteine), and statins ( Table 1 ) .
For
Some of the oral medications (eg, antibiotics, corticosteroids) are primarily prescribed to treat acute exacerbations of COPD. In this review, we did not assess the interventions used to treat acute exacerbations; we evaluated the evidence around the use of the interventions to prevent or decrease acute exacerbations.
Antibiotics:
Macrolide antibiotics have a number of antimicrobial, antiinfl ammatory, and immunomodulating effects and have been used for many years in the management of other chronic airway diseases, including diff use panbronchiolitis and cystic fi brosis. Given this successful use and the signifi cant role airway infl ammation and bacterial infection play in the pathogenesis of COPD exacerbations, there has been increasing interest in the use of macrolides to prevent these events.
Five RCTs comparing the administration of a macrolide vs placebo or another agent were identifi ed for fi nal inclusion of which three were ultimately included in the analysis on the basis of matched outcomes. 21 21 fewer patients in the azithromycin group developed nasopharyngeal colonization during the study with common respiratory pathogens, but those who did were more likely to become colonized with organisms that were resistant to azithromycin. Th e signifi cance of these findings is uncertain because colonization was not associated with an increase in COPD exacerbations or pneumonia. Th ere was also a modest increase in the risk of hearing loss in those assigned to azithromycin, although this oft en was reversible.
Although there was no increase in the risk of adverse cardiovascular events in patients taking azithromycin in the study by Albert et al, 21 other large population-based studies suggested that the drug may increase the risk of cardiac death, and thus, patients should be carefully evaluated for predisposing conditions or medications before initiating therapy. Th e cardiac safety of azithromycin in the study by Albert et al 21 may be partly due to excluding patients with QT prolongation or who were taking other drugs that could prolong the QT interval. Th e data from the available clinical trials demonstrate that regular macrolide therapy defi nitively reduces the risk of acute exacerbations. Although these results are robust and would support a level 1 recommendation, safety data from the largest of these studies (Albert et al 21 ) raise concerns about the development of antibiotic resistance as well as hearing loss. In addition, data from large observational studies in other populations suggest the potential for cardiovascular side eff ects, including prolongation of the QT interval, although these were not observed in the randomized trials reviewed for these guidelines. Based on these potential safety concerns, macrolide therapy is suggested (grade 2A) as a therapeutic option in patients with a history of exacerbations, and clinicians should be aware of the potential for adverse eff ects. Th e duration and exact dosage of macrolide therapy is unknown, but given the effi cacy of the macrolides, strategies to mitigate these potential adverse eff ects are recommended.
Underlying Values and Preferences:
Corticosteroids: Systemic oral corticosteroids for the long-term treatment of COPD are not recommended (GOLD guidelines), but their use is recommended for treating acute exacerbations of COPD (GOLD guidelines). 1 Systemic corticosteroids have been shown to improve symptoms and lung function, reduce treatment failure, and shorten length of hospital stay. 224 -227 Th e eff ect of preventing a subsequent exacerbation is more controversial and was the focus of our review.
Four studies addressed hospitalization within 30 days following an exacerbation, 224 , 226 , 228 , 229 whereas two studies addressed hospitalization for acute exacerbations of COPD at 6 months. 226 
We place high value on reducing recurrent exacerbations in the fi rst 30 days following an initial acute exacerbation of COPD by treating the exacerbation with systemic corticosteroids. Th is recommendation takes into consideration the risks associated with the short-term use of systemic corticosteroids, which include hyperglycemia, weight gain, and insomnia, but the benefi ts of this intervention are believed to outweigh the risks. Th e use of systemic corticosteroids to treat an acute exacerbation has not been shown to reduce acute exacerbations beyond the 30-day window. Furthermore, no evidence supports the use of long-term corticosteroids to reduce acute exacerbations of COPD, and the risks of hyperglycemia, weight gain, infection, osteoporosis, and adrenal suppression far outweigh any benefi ts.
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Underlying Values and Preferences:
We place high value on reducing recurrent exacerbations in the fi rst 30 days following an initial acute exacerbation of COPD by treating the exacerbation with systemic corticosteroids. Th is recommendation takes into consideration the risks associated with the short-term use of systemic corticosteroids, which include hyperglycemia, weight gain, and insomnia, but the benefi ts of this intervention are believed to outweigh the risks. Th e use of systemic corticosteroids to treat an acute exacerbation has not been shown to reduce acute exacerbations beyond the 30-day window. Furthermore, no evidence supports the use of long-term corticosteroids to reduce AECOPD, and the risks of hyperglycemia, weight gain, infection, osteoporosis, and adrenal suppression far outweigh any benefi ts.
Phosphodiesterase 4 Inhibitor:
Th e phosphodiesterase 4 inhibitor rofl umilast has been evaluated for its ability to prevent future exacerbations in patients with moderate to severe COPD with a history of chronic cough and sputum production and exacerbations. Two of the included studies 231 , 232 were large, placebo-controlled, multicenter trials. Th e results from the centers participating in the Calverley et al 231 trial were pooled because the protocols were identical for the participating centers. Fabbri et al 232 conducted four studies comparing rofl umilast with placebo; one compared rofl umilast and either salmeterol or tiotropium with bronchodilator alone and, therefore, was analyzed as two separate studies. One study 221 was actually a post hoc analysis of the two studies reported in Calverley et al 231 and looked at the value of rofl umilast in reducing the frequency of COPD exacerbations in the frequent exacerbator phenotype (two or more exacerbations in the previous year) compared with the infrequent exacerbator phenotype. One study 233 had FEV 1 as a primary outcome and COPD exacerbations as a secondary outcome. Because the study was only 12 weeks long and the number of exacerbations was low in both the placebo and the rofl umilast groups, this study was excluded from the pooled data.
We were able to match three studies, one from Calverley et al 231 [ 1 4 7 # 4 C H E S T A P R I L 2 0 1 5 ]
Each included trial for the pooled exacerbation data was large and well designed. However, they only included a subset of patients with COPD with grade III or IV obstruction (FEV 1 , 50% predicted), a history of chronic bronchitis, and at least one reported exacerbation requiring treatment or hospitalization in the previous year. Th ere were a number of medication exclusions for the trials. Most excluded the use of theophylline and inhaled corticosteroids. 221 , 231 , 232 More than 40% of patients in the rofl umilast and placebo groups had been treated with long-term inhaled corticosteroids prior to the studies, and previous studies suggested that inhaled corticosteroid withdrawal may be associated with an increased subsequent risk of exacerbations. Long-term use of inhaled corticosteroids up to 2,000 m g beclomethasone equivalents was allowed in the study by Calverley et al. 151 Th is may explain the somewhat lower mean exacerbation rate in both the placebo and the rofl umilast groups in this study compared with the other studies that excluded inhaled corticosteroids. However, the benefi t of rofl umilast in reducing exacerbations was similar between subjects previously on inhaled corticosteroids and those who were not in the latter studies.
Th e use of long-acting muscarinic agents was excluded in each study aside from Fabbri et al, 232 which specifi cally looked at the benefi t of rofl umilast vs placebo added to tiotropium. The use of long-acting b -agonists was excluded from the study by Calverley et al. 151 Each study had a number of secondary end points, including prebronchodilator and postbronchodilator FEV 1 , both values of which increased by a statistically signifi cant amount. Th e improvements in prebronchodilator FEV 1 between the rofl umilast and placebo groups ranged from 39 151 to 80 mL when added to tiotropium. 232 Th e postbronchodilator improvement ranged from 36 151 to 81 mL when added to tiotropium. 232 In a smaller study by Lee et al 233 looking at the benefi t of rofl umilast vs placebo in Asian patients with COPD with slightly less severe airfl ow obstruction compared with those enrolled in the exacerbation studies, improvements in prebronchodilator FEV 1 averaged 95 mL and postbronchodilator FEV 1 79 mL (both P , .0001).
Side eff ects of nausea, diarrhea, headache, and weight loss averaging about 2.1 kg were more common in the rofl umilast-treated patients and led to increased patient withdrawals from the study, particularly in the fi rst 3 to 4 weeks. Th e side eff ects may limit the use of this medication in the clinical setting.
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For patients with moderate to severe COPD with chronic bronchitis and a history of at least one exacerbation in the previous year, we suggest the use of rofl umilast to prevent acute exacerbations of COPD (Grade 2A) .
Underlying Values and Preferences:
Th eophylline: Th eophylline has been used to treat airway diseases for decades. Its bronchodilator eff ects are mediated through inhibition of phosphodiesterase 3, 234 although this requires fairly high serum levels, which are associated with frequent side eff ects of nausea, vomiting, and gastroesophageal refl ux as well as headache. At lower doses, theophylline also likely has antiinfl ammatory effects, although these may be mediated through phosphodiesterase 4 inhibition and activation of histone deacetylase 2, which downregulates a number of inflammatory genes. Th e drug is metabolized by the hepatic cytochrome p450 system and, thus, has a number of important drug interactions. As a bron chodilator in patients with COPD, theophylline improves lung function when added to long-acting b -agonists, and there is some evidence that it may reverse corticosteroid resistance in this group.
Of the 18 studies of oral theophylline compared with placebo, an active comparator, or both, two met criteria for further review. 235 , 236 Rossi et al 235 randomized 854 patients with COPD (FEV 1 , 70% predicted) to one of two doses of formoterol (12 or 24 m g bid), oral slow-release theophylline twice daily and titrated to 8 to 20 mg/L 3 to 4 h aft er dosing, or placebo for 1 year. Th e primary end point was FEV 1 , but the number of patients experiencing moderate to severe exacerbations was also assessed and shown to be reduced in both the formoterol dosage arms compared with placebo. Th ere was no diff erence in the number of patients with exacerbations in the theophylline vs placebo arms. GI side eff ects were threefold higher in those receiving theophylline than either formoterol arm, and this led to a 27% withdrawal rate in the fi rst 3 months of the study. Zhou et al 236 Physicians should use the lowest eff ective dose in prescribing theophylline in order to avoid adverse eff ects. Th eophylline use requires vigilance on the part of the physician in order to avoid serious drug interactions, which lead to changes in serum theophylline levels. Patients should be advised that changes in tobacco use habits will aff ect serum theophylline levels and that they should inform their physicians if they stop smoking while taking theophylline.
N-acetylcysteine:
Patients with COPD and chronic bronchitis may experience exacerbations of their condition because of thick secretions that are diffi cult to eliminate from the tracheobronchial tree. NAC has been proposed as an agent that may act as a mucolytic in the respiratory tract and aid in the elimination of secretions. NAC reduces the viscosity of respiratory secretions as a result of the cleavage of disulfi de bonds. 237 In patients with COPD and chronic bronchitis, oral NAC has been proposed as a mucolytic agent because it is rapidly absorbed from the GI tract, has been reported to be rapidly present aft er ingestion in an active form in lung tissue and respiratory secretions, and is well tolerated except for in rare patients with adverse GI eff ects. 238 Investigators fi rst suggested that NAC might be eff ective in reducing exacerbations of COPD more than 3 decades ago. 238 , 239 We identifi ed 11 RCTs comparing the administration of NAC with placebo or another agent, of which three were ultimately included in the meta-analysis based on matched outcomes. 240 -242 Th e other studies 243 -248 were either not conducted at the patient level but, instead, at the exacerbation count level or had exacerbations as a secondary outcome measure.
Hansen et al 240 randomized 129 patients to a prospective, placebo-controlled, double-blind study with oral NAC administered twice daily as the study intervention. Th e authors found an improvement in subjective complaints using the General Health Score, an established psychiatric instrument measuring symptomatic well-being. Th is fi nding was mitigated by scores being diff erent between the two groups at baseline. Th e number of exacerbations in the NAC group was not signifi cantly diff erent from that in the placebo group.
Pela et al 241 studied 169 patients randomized to receive oral NAC 600 mg once daily vs placebo. Th e primary outcome measurement was the rate of COPD exacerbations, which was reduced by 41% in the intervention group compared with the control group. Th e study drug reduced the number of patients having multiple exacerbations, and pulmonary function measurements were slightly, but signifi cantly improved. NAC was well tolerated, with no diff erence in adverse events between groups.
In the largest study to date by Zheng et al 242 randomized 1,006 patients to receive oral NAC 600 mg bid vs placebo. Th is study was a large, multicenter, prospective, placebocontrolled, parallel group trial performed in China.
Patients were selected if they had moderate to severe COPD based on spirometric measurements, were aged 40 to 80 years, and had at least two COPD exacerbations within the 2 years prior to enrollment. Patients were also stratifi ed according to their use of inhaled corticosteroids. Th e exacerbation rate was 1.16 in the NAC group vs 1.49 in the placebo group (RR, 0.78 for the NAC group). Time to fi rst exacerbation was not diff erent between the study and placebo groups, but time to second and third exacerbations was shorter in the placebo arm. NAC appeared to be more eff ective in patients with GOLD II COPD compared with those with GOLD III, with time to fi rst exacerbation being longer in the GOLD II group than in the GOLD III group. Th e incidence of adverse eff ects attributed to the study drug did not diff er between the NAC and placebo groups.
When examined together, the combined data from these studies 240 -242 demonstrate a reduction in the rate of exacerbations in COPD associated with the use of NAC compared with placebo (OR, 0.61; 95% CI, 0.37-0.99). Although conclusions are limited by the sample size of the studies assessed, oral NAC is well tolerated and appears to represent a low risk to patients.
31.
Underlying Values and Preferences:
Erdosteine: Erdosteine, a mucolytic, has potential to reduce exacerbations in patients with COPD. Th e only study identifi ed in the systematic review was a small RCT in 124 patients over 8 months. 249 Th erefore, we determined that insuffi cient evidence supports a recommendation about the use of erdosteine for the prevention of COPD exacerbations.
Carbocysteine: S-carboxymethylcysteine (carbocysteine or S-CMC) is a thiol derivative of l -cysteine and is available as carbocysteine or its lysine salt (S-CMC-lys), which is cleaved in the GI tract to the active drug carbocysteine. Th is drug is a mucolytic agent available in Europe and Asia that has been demonstrated to reduce sputum viscosity and increase mucociliary transport. 250 Only three studies 251 -253 were deemed to be of suffi cient quality to be included, but a pooled analysis could not be performed because of the heterogeneous nature of the studies. S-CMC-lys was given to patients in a multicenter randomized placebo-controlled trial performed in 662 outpatients with chronic obstructive bronchitis. 252 Patients were randomized to S-CMC-Lys daily, placebo, or intermittent treatment with alternating 1-week courses of S-CMC-Lys and placebo for 6 months. The percentage of patients who were exacerbation free during the 6-month trial was signifi cantly greater in the group randomized to once daily S-CMC-Lys compared with placebo (70.4% vs 54.1%, P 5 .001), and the time to a fi rst AECOPD was prolonged compared with placebo. Another trial enrolled 109 patients with obstructive chronic bronchitis to either carbocysteine or placebo for a 6-month winter period, but the investigators found no diff erence in the number of acute exacerbations of chronic bronchitis between the two groups. 252 Th e largest study to date has been the PEACE Study (Eff ect of Carbocysteine on Acute Exacerbation of COPD), which randomized 709 outpatients with COPD with a history of at least two acute exacerbations of COPD in the previous 2 years to either placebo or carbocysteine for 1 year. There was a significant reduction in the number of exacerbations in the carbocysteine group compared with the placebo group (RR, 0.75; 95% CI, 0.62-0.92) with the diff erence becoming signifi cant aft er 6 months of therapy. 253 Th ese studies did not permit a pooled analysis; therefore, we can only suggest that carbocysteine may be benefi cial in reducing acute exacerbations of COPD, but more data from randomized placebo-controlled clinical trials are needed before an evidence-based recommendation can be made.
32. For stable outpatients with COPD who continue to experience acute exacerbations of COPD despite maximal therapy designed to reduce acute exacerbations of COPD, we suggest that oral carbocysteine could be used to prevent acute exacerbations where this therapy is available (Ungraded Consensus-Based Statement).
Statins:
Statins are well-known and widely prescribed for their lipid-lowering eff ects and improved outcomes related to cardiovascular disease. Statins are also known for their pleotropic eff ects, which include an antiinfl ammatory eff ect. In view of this attribute, statins have been evaluated for their role in preventing COPD exacerbations.
We found fi ve observational studies 254 -258 
Underlying Values and Preferences:
We place high value on reducing exacerbations in patients with COPD and, thus, do not recommend statins for preventing acute exacerbations. However, patients with COPD may meet accepted criteria for initiating statins because of the presence of cardiovascular risk factors.
Novel Therapies Not Included in the Guidelines
Several novel therapies are now in various stages of development for use alone or in combination with other agents in the management of COPD. Studies examining the eff ect of these agents on COPD exacerbations are either nonexistent or too small to include in the current guidelines. A short description of such agents is included here.
Most of the novel agents that have been recently approved or are in late stages of development include once-daily long-acting b 2 -agonists olodaterol and vilanterol and long-acting muscarinic antagonists umeclidinium and glycopyrronium delivered through novel delivery devices. Olodaterol, recently approved by the US Food and Drug Administration for COPD is a new inhaled ultralong-acting b -agonist that off ers the potential adherence and therapeutic advantage of once-daily therapy. 260 , 261 Additionally, multiple formulations of once-daily agents that use combinations of long-acting b 2 -agonists and long-acting muscarinic antagonists (vilanterol/umeclidinium, tiotropium/ olodaterol, aclidinium/formoterol, glycopyrronium/ indacaterol, glycopyrronium/formoterol) are under development. 221 , 262 -274 One such combination is vilanterol/umeclidinium that was recently approved by the Food and Drug Administration for COPD as once-daily combination bronchodilator therapy. 275 -278 Similarly, once-daily long-acting b 2 -agonist/inhaled corticosteroid formulations are being investigated. One such agent recently approved is fluticasone furoate/vilanterol, and several studies reported that this combination improves lung function and reduces exacerbations more eff ectively than either of its monocomponents. 188 , 191 , 194 , 197 , 279 , 280 A large long-term study investigating fl uticasone furoate/vilanterol in patients with cardiovascular risk factors (SUMMIT [Study to Understand Mortality and Morbidity in COPD]) is currently under way. 281 Other novel agents in early development are those that target airway infl ammation in COPD, such as adenosine A2A-receptor agonists, inhibitors of proinfl ammatory pathways, and activators of antiinfl ammatory pathways. Among these are mimics of IL-10 and inhibitors of (1) tumor necrosis factor-a , (2) chemokines, (3) nuclear factor-k B; (4) p38 mitogen-activated protein kinase, (5) phosphoinositide 3-kinase, and (6) leukotriene B4.
Other drugs under investigation include those with antioxidant eff ects and that may have eff ects on lung regeneration (retinoids) as well as mucoactive drugs. 184 , 185 , 270 , 282 -285 Conclusions Th ese guidelines provide the clinician with evidencebased information on therapies to prevent COPD exacerbations using an objective, rigorous, evidencebased approach to the assessment of the existing literature regarding nonpharmacologic inhaled and oral therapies (Fig 1) . We have avoided providing opinions, instead using objective assessment of each recommendation where the data are robust enough to provide a meaningful conclusion based on the available data. Th is assessment also highlights areas where more research is needed as demonstrated by CB recommendations as well as recommendations given a grade of C. It is clear that large gaps in knowledge currently exist about exacerbation prevention that limit our ability to prioritize one type of therapy over another or make recommendations about combinations of therapy to prevent exacerbations. Hopefully, future research will evaluate combinations of therapies across PICO groups and their impact on exacer bation prevention. Newer therapies that are soon to be released for clinical use or that are currently under investigation that focus on the prevention of COPD exacerbations also promise to rapidly improve the future armamentarium for the treatment of the patient with COPD.
Sandra Zelman Lewis, PhD; and Marianne Wright, BS (Dr Lewis and Ms Wright helped in the early stages of the guideline) for their tireless eff orts to make this guideline a current and valuable addition to the management of the patient with COPD.
Additional information:
Th e e-Appendix and e-Tables can be found in the Supplemental Materials section of the online article.
